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i) Abstract  
Background: Due to increased rates of survival for children with cancer*, many 
now maintain their fertility into adulthood. Long-term chronic conditions of 
female childhood cancer survivors (CCS), coupled with physiological pressures 
of pregnancy and birth warrants further investigation by health care providers.  
Objectives: To investigate the impact upon live birth outcome for female CCS 
who received radiotherapy to the flank, abdomen or pelvic areas. A Patient and 
public involvement and engagement (PPIE) survey was used to align the review 
outcomes to patient need and results were presented.     
Data sources: A search of MEDLINE, PUBMED, CINAHL, Google Scholar, 
TRIP, SCOPUS and ProQuest databases was undertaken until 30th September 
2017.  
Study criteria and participants: 
• Female CCS treated with radiotherapy to the flank, abdomen or pelvis 
• English language publications  
• Population data from a recognised data registry and from UK, USA, 
Canada, Australia or EU  
• Quantitative methodology 
 
Appraisal and synthesis: Data were extracted, and meta-analysis performed 
with EPPI Reviewer4 software. The Newcastle Ottawa scale was used for risk 
of bias assessment. 
Results: A statistically significant effect upon the odds of a premature birth 
(odds ratio 3.27, 95% CI 2.71-3.96) and stillbirth (odds ratio 1.62, 95% CI1.10-
2.40) was noted. There was no statistically significant effect on live birth 
outcome or additional adverse pregnancy outcomes. The PPIE survey 
demonstrated that ‘maternal complications in pregnancy and birth’ was the 
primary concern of CCS with a call for more communication of likelihood of 
long-term complications related to cancer treatments.     
Limitations: Limitations were noted with software, heterogeneity of outcomes, 
lack of evidence and a reliance on self-reported data.  
Conclusions: Female CCS treated with radiotherapy to the flank, abdomen or 
pelvis need high risk antenatal care referral and surveillance due to increased 
odds of premature birth and stillbirth.  
Registration: PROSPERO ID- CRD42017054533    
* Throughout this thesis, unless explicitly specified, the word children and childhood will 
be used to mean children, teenagers and young adults 0-24 years.  
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ii) Glossary and abbreviations 





A type of blood cancer that arises from young white 
blood cells called lymphocytes in the bone marrow 
Anthracyclines A class of drugs used in chemotherapy 
ART Artificial reproductive technologies 
ATHENS An online account which facilitates searching on 
information databases 
Atrophy  Wastage of a body tissue or organ 
Autologous Cells obtained from the same individual 
BCCSS The British Childhood Cancer Survivorship Study 
Cardio-toxic Toxic or damaging to the heart 
Cardiovascular 
disease 
A class of diseases that involve the heart or blood 
vessels 
CCS Childhood cancer survivors 
CCSS The Childhood Cancer Survivorship study 
CI Confidence interval 
CTIMP Clinical Trial of an Investigational Medicinal Product 
DIPG Diffuse intrinsic pontine gliomas, a highly aggressive 
brain tumour 
DNA Deoxyribonucleic acid (genetic make-up) 
Embryonal tumour A mass of rapidly growing cells that begin in embryonic 
(fetal) tissue 
EU European Union 
Fibrosis The thickening or scarring of tissue 
Flank The side of the body between the ribs and the hip 
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Germ cell tumour A type of cancer that originates in the ovaries or testes 
and derives from germ cells 
Gy Grey (measurement of dose in radiotherapy) 
HEE Health Education England 
Hodgkin’s 
Lymphoma 
a type of lymphoma resulting from the white blood 
cells, usually presents in the lymph nodes 
ICCC International classification of childhood cancers 
IMRT Intensity Modulated Arc Therapy. A precision delivery 
radiotherapy treatment   
INVOLVE A national advisory group for patient and public 
involvement in research funded by the NIHR 
IRAS Integrated Research Application system 
IVF In vitro fertilization 
Lymphoma A type of cancer that begins in the infection fighting 
cells of the immune system called lymphocytes 
Malignancy Cancer 
 
Malposition of the 
fetus 
 
A position of the fetus in labour that is not optimal for 
birth 
Menarche The first occurrence of menstruation 
MeSH Medical subject headings used in databases 
Metastases Secondary cancerous growths at a distance from the 
primary tumour site 
Myometrium The middle layer of the uterine wall 
Neuroblastoma A type of cancer which forms in the nerve tissues 
NHS National Health Service 
NICE National Institute for Health and Care Excellence 
NIHR National Institute for Health Research 
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NOS Newcastle Ottawa Scale 
OR Odds ratio. The OR measures the ratio of the odds 
that an event or result will occur compared to the odds 
of the event not happening. Clinically, that often means 
that the researcher measures the ratio of the odds of a 
disease occurring or a death from a specific injury or 
illness happening versus the odds of the disease or 
death not occurring  
PANCARE A multidisciplinary pan-European network of 
professionals, survivors and families aiming to reduce 
the frequency, severity and impact of late side-effects 
of childhood and adolescent cancer 
Parturition The action of giving birth 
PDF Portable Document Format 
Pelvis The lower part of the trunk of the body between the 
abdomen and the thighs 
Placenta praevia A pregnancy condition where the placenta lies low in 
the uterus and partially or completely covers the cervix 
PPIE Patient and Public Involvement and Engagement 
PRISMA An evidence-based set of reporting guidelines for 
systematic reviews and meta-analysis 
PROM  Premature rupture of membranes  
PROSPERO An international database of prospectively registered 
systematic reviews in health and social care 
Proton Beam 
therapy 
Type of radiotherapy that uses protons to treat cancer 
RCM Royal College of Midwives 
RCOG Royal College of Obstetricians and Gynaecologists 
RCT Randomised controlled trial 




Rhabdomyosarcoma A type of sarcoma 
RR Risk ratio. In statistics and epidemiology, relative risk 
or risk ratio (RR) is the ratio or probability of an event 
occurring (for example, developing a disease, being 
injured) in an exposed group versus the probability of 
the event occurring in a comparison, non-exposed 
group 
Sarcoma Rare cancers that develop in the muscle, bone, 
nerves, cartilage, tendons, blood vessels and fibrous 
tissues 
SIGN Scottish Intercollegiate Guidelines Network 
TYA  Teenage and Young Adult 
USA United States of America 
UK United Kingdom 
Wilms tumour Also known as nephroblastoma is a kidney cancer 
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Chapter 1 – Introduction  
The survival rate for Children and Teenagers and Young Adults (TYA’s) with 
cancer is now approximately 80 percent (Clic Sargent 2016). Despite this, 
cancer treatments delivered to a child or young person are known to cause 
significant long-term* chronic health problems in adulthood (Clic Sargent 2016, 
Aslett et al. 2007).  
Many female childhood cancer survivors (CCS) now maintain their fertility in 
adulthood (Reulen et al. 2017). Research has not adequately addressed the 
impact of chronic and treatment-related health conditions, combined with 
anatomical and physiological pressures of pregnancy and birth on the female 
CCS and their babies. There is an important and vital knowledge gap for health 
care providers who provide obstetric care to a CCS to ensure optimal outcomes 
for both mother and baby are achieved.  
This thesis provides a systematic review and meta-analysis of the existing 
evidence investigating the long-term effect of radiotherapy on outcome of live 
birth and associated pregnancy adverse events. The researcher, a midwife by 
profession, has employed extensive experience in being involved and running 
Patient and public involvement and engagement (PPIE) events and has aimed 
to incorporate a patient-centred approach to the review with the inclusion of a 





1.1  Background  
*Long-term in this review is defined as an outcome or clinical health or psychological health issue of 




This chapter will outline the incidence of childhood cancer and survival rates, 
the biology underlying the disease and the effects of radiotherapy on the female 
anatomy, and an overview of survivorship research. The chapter will then 
consider the challenge of addressing complex health conditions in maternity 
services and conclude with the aim, rationale and outline of this review.    
1.1.1 Childhood Cancer – Incidence and survival rates  
  
Annually, 1800 children under 15 and around 2,200 15 to 24-year-olds are 
diagnosed with cancer every year in the UK (Children with Cancer UK 2018). 
The 15-24-year age group is referred to as ‘teenage and young adult’ or ‘TYA’. 
Childhood cancers are classified into cancer types using the International 








**In this review, the researcher has chosen to include children and TYA groups with cancer (0-24 years) within 
the term ‘childhood’ to provide an accurate and extensive representation of all childhood/teenage/young 
adult specific cancers which may arise until age 24. 
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Figure 1 - Childhood cancer incidence by type 
(Childhood Cancers by Cancer Type, Average Number of New Cases per Year, Ages 0-14, Great 




Advances in childhood cancer treatment have evolved dramatically since 1960, 
where survival rates were less than 30 percent at five years’ post treatment 
(Cancer Research UK 2018). The rise in survival is largely attributed to the 
introduction of chemotherapy, a greater understanding of the aetiology of 
cancer and risk stratification methods (Cancer Research 2018). Despite survival 
rates across all malignancies at around 80% (Children with Cancer UK 2018), 
there is still a marked variation in survival rates between malignancies such as 
DIPG or bone cancer (Children with Cancer UK 2018).  
Improved survival rates now provide the opportunity for CCS to lead a life that is 
comparable to the general population, including having a family of their own 
(Fallat and Hutter 2008, Wallace, Thompson and Anderson 2013).  
1.1.2  Biological features of childhood cancer 
  
There are multiple and complex types and subtypes of childhood cancers. 
Biologically, childhood cancer develops, mutates and reacts differently to 
treatment than adult cancer; therefore, treatments, dosages, protocols and 
toxicity of treatments for children vary greatly from adults (Cancer Research UK 
(CRUK) 2018).  
Treatment for childhood cancer typically includes a combination of 
chemotherapy, radiotherapy, surgery and immunotherapy treatments (CRUK 
2018). Chemotherapy works by mutating the deoxyribonucleic acid (DNA) of the 
child to stop the cancer from replicating (CRUK 2018). Radiotherapy can be 
used in treatment of targeted areas of the body including the entire chest, 
abdomen and brain to control disease and prevent relapse (CRUK 2018) and 
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surgery can include organ removal and amputation. Some childhood cancer 
treatment protocols also now include autologous or donor bone marrow 
transplantation and novel immunotherapy treatments (CRUK 2018).  
Not all childhood cancers receive all treatment modalities, however almost all 
receive chemotherapy as a standard treatment (CRUK 2018). The Royal 
College of Radiologists (RCOR) (source Saunders via RCOR members update 
2018) surmises that out of an approximate 1800 new cases of childhood cancer 
per annum, 40 percent of children will receive radiotherapy (conventional or 
proton) as part of their treatment (RCOR, source Saunders via RCOR members 
update 2018). Figure 2 illustrates the percentage of childhood cancer 
malignancies that are likely to receive radiotherapy as standard treatment: 
Figure 2 - Childhood malignancies that receive radiotherapy 


























The use of radiotherapy to the flank, abdomen or pelvic areas is dependent on 
the site and type of tumour, the location of any tumour deposits and often sub-
classifications related to risk of recurrence and degree of response to other 
treatments (Saunders 2015).  
Tumours that often receive radiotherapy to the flank, abdomen or pelvis include 
Wilms tumour, neuroblastoma, leukaemia (when total body irradiation is used), 
Hodgkin lymphoma, sarcomas and germ cell tumours. This list is not exhaustive 
or exclusive and is dependent on the site of the tumour and/or metastases and 
the recommended treatment protocols (Saunders 2015).  
1.1.3  Biological effects of radiotherapy on the uterus 
   
During puberty, the growth of the uterus commences before the appearance of 
external sexual characteristics and is not completed until around 7 years after 
menarche (Teh et al. 2014:2). Radiotherapy delivered to the uterine area in a 
child that has yet to reach puberty, has been suggested by Revelli et al. (2007) 
to increase the likelihood of abnormal organ development and growth, 
increasing likelihood of adverse pregnancy and birth outcomes. The pre-
menarche uterus has also been suggested to be more sensitive to radiation-
induced adverse effects (Revelli et al. 2007). Larsen et al. (2004) equally 
supported the view that uterine radiotherapy at a young age reduces adult 
uterine volume and that the radiotherapy-induced damage is probably 
irreversible. The timing of treatment and dosages was also suggested to be an 
important variable for perinatal risk by Signorello et al. (2006), Reulen et al. 
(2009) and Lie Fong (2010). 
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Biological indicators of radiotherapy damage to the uterus include decreased 
uterine blood flow, endometrial and myometrial atrophy, decreased uterine 
elasticity and uterine fibrosis (Critchley et al. 1992:394). This type of damage to 
the uterus has been linked to adverse perinatal outcomes (Critchley et al. 
1992). It has also been suggested that abnormal placental formation and 
abnormal conversion of uterine spiral and distal arteries (due to radiotherapy 
damage), could subsequently increase the risk of abnormal placentation 
(placenta praevia, percreta or accreta), uterine rupture, miscarriage, preterm 
and low birth weight babies and cervical insufficiency leading to late miscarriage 
during pregnancy (Revelli et al. 2007:805, Kalapurakal et al. 2004:1366, 
Critchley et al. 1992:395). Signorello et al. (2006) further supports these 
findings by linking female CCS treated with flank, abdominal and pelvic 
radiotherapy with an increased risk of premature delivery, miscarriage, stillbirth 
and delivering low birth weight babies.  
 
Reulen et al. (2009:2245) reported that although pregnancy rates of CCS were 
found to be less than sibling and general population controls and that they 
produced fewer offspring in total, female CCS, that subsequently became 
pregnant and who had prior exposure to abdominal radiotherapy, carried a 
significant biological risk in pregnancy due to increasing myometrial fibrosis of 
the uterus. This echoes previous research by Revelli et al. (2007), linking 
abnormal vascular and/or muscular development of the uterus to radiotherapy 
exposure as a child. Reulen et al. (2009:2243) also linked this abnormal 
development of the uterine muscles to an increased inability of a female CCS to 




Although this evidence is limited and largely out-dated case-study evidence, it 
strongly suggests that damage caused by radiotherapy might be a key factor to 
adverse pregnancy and birth outcomes, impacting on the live birth rate and 
associated adverse outcomes of CCS. As the authors suggest, more research 
is desperately needed to be conclusive for accurate claims of long-term damage 
to the uterus caused by radiotherapy and the impact upon female CCS in 
pregnancy.  
1.1.4  Survivorship research – An overview 
  
The population of CCS in society has grown significantly. In 2005 it was 
reported that 26,000 people in the UK were long-term*** CCS, (CRUK 2018). 
Children with Cancer UK (2018) also estimate that there are now over 35,000 
CCS in the UK and this is growing by 1,300 per year.  
Long-term (>5 years post treatment completion) health outcomes of CCS is a 
rapidly growing area of interest for both CCS, their families and professionals 
(Aslett et. al 2007:1782). Up to 30 percent of CCS are left with long-term effects 
caused by either the cancer itself or the treatment required to cure the cancer 
(Clic Sargent 2016).  
 
Late effects can include problems with growth, mobility, organ function, fertility, 
cognition and academic achievement (Aslett 2007:1782). At least two thirds of 
***A Long-term CCS is defined in this review as a survivor of childhood/teenage/young adult cancer 
still alive >5 years since diagnosis. 
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CCS develop at least one late-onset treatment-related complication in 
adulthood (Aslett 2007:1782).  
Figure 3 - Long term outcomes CCS  
(Reproduced from PAC2 (adapted from Hudson 2013, accessed on 30th April 
2018) 
 
Although research into the long-term effects of childhood cancer treatments is 
an emerging area of interest both in the USA and Europe (Aslett et. al 
2007:1782), research into pregnancy outcomes of CCS has been limited. This 
is despite fertility and pregnancy being reported as a significant concern for 
CCS and their families (Benedict, Shuk and Ford 2016, Teh et al. 2014).   
Research into pregnancy outcomes of CCS has largely compromised of 
epidemiological studies, which have used small sample sizes; varied greatly in 
methodological approach, have varied greatly in the selection of patient/control 





22% LIVE - with no long-term or
chronic health conditions
34% DIE - within 30 years (20%
years 1-5 and 14% years 6-30
19% SURVIVE - but suffer with life-
limiting and long-term health
complications
25% SURVIVE - but suffer with mild




treatment modality analysis (Chiarelli et al. 2000, Melin et al. 2015, Meuller et 
al. 2009 and Winther et al. 2008). 
An organisation specifically set up to address issues of CCS (Multidisciplinary, 
pan-European network for survivors of childhood cancer (PANCARE)), has 
resulted in an array of international guidelines and published work into long-
term health outcomes of CCS, including guidance for antenatal screening and 
pregnancy care of CCS at risk of heart disease from chemotherapy treatments 
(Armenian et al. 2015). Despite acknowledging cardiovascular disease as an 
important issue for CCS in pregnancy, there has not been a guideline published 
to date addressing the needs of CCS who have received radiotherapy 
treatment. This is despite several international retrospective cohort studies 
demonstrating an increased risk of premature delivery and low birth weight 
babies for female CCS treated with radiotherapy (Signorello et al. 2006, Reulen 
et al. 2009).  
Survivorship research investigating long-term outcomes of CCS is an emerging 
area if interest for both professionals and CCS, however pregnancy and birth 
outcomes of CCS has been shown to be an area that requires further work.   
1.1.5  Complex health conditions in maternity services 
    
An increasing number of physically complex pregnant women with pre-existing 
co-morbidities now routinely present for maternity care (NHS England 2016a:3). 
Specific care pathways to meet the complex medical and psychological needs 
of women in pregnancy and birth have been published for conditions such as 
diabetes, epilepsy and women with complex cardiovascular conditions (Smith, 
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Dixon and Page 2009: 21). These pathways have been successfully introduced 
into the National Health Service (NHS) with National Institute of Health and 
Care Excellence (NICE) accreditation and adoption by the Royal College of 
Midwives (RCM) and Royal College of Obstetricians and Gynaecologists 
(RCOG). This has allowed for quick clinical implementation and patient impact, 
optimising care and outcomes for families based upon evidence-based 
research. 
There are no maternity guidelines for the management of care for CCS in 
pregnancy, or for any women who present with a history of adult cancer (except 
for breast cancer where a clinical guideline does exist (Dow 2000)). This could 
be explained by a lack of awareness of specific needs within this rare disease 
group or a lack high-quality, collated evidence for this issue. 
1.2  Rationale for the review 
 
This systematic review and meta-analysis are unique, as no clinician with a 
maternity or obstetric background has attempted to answer this question with a 
systematic approach. Despite acknowledgement of data that highlights the 
increased likelihood of adverse pregnancy outcomes in female CCS, research 
has been largely conducted by epidemiologists and paediatric oncology 
specialists. This has led to a lack of clear and focused recommendations when 
attempting to address exactly what is needed in a maternity care package for 
female CCS. This review is also the first to include patient and public 
involvement and engagement (PPIE), which was used to align patient needs or 
concerns in this area with selected outcomes by the researcher. The researcher 
has also ensured that PPIE involvement within the dissemination plan and with 
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a lay-summary for findings is included, which has not been employed into 
previous systematic review design.   
As a midwife by profession, the researcher understands the need for accurate 
and evidence-based information for maternity care services, empowering 
women to make informed choices and providing evidence for obstetricians and 
midwives to enable birth choices and screening choices. The researcher aims 
to share results from this review not only paediatric oncology care specialists 
but also maternity organisations and stakeholders, allowing for wider 
dissemination between clinical specialities with the intent to allow quicker 
patient impact and implementation of findings. This might allow for further 
research in this field and an evidence base to support interventional research 
projects.  
The existing evidence suggests that childhood cancer survivorship research is 
of importance to both health care professionals, researchers and CCS and their 
families (Benedict, Shuk and Ford 2016, Teh et al. 2014). CCS represent a 
patient cohort susceptible not only to increased likelihood of co-morbidities 
throughout the life span (directly attributable to prior cancer treatment), but who 
are also at an increased likelihood of adverse pregnancy and birth outcome.  
Further research into this patient cohort is pertinent for maternity services to 
enable effective planning of midwifery and obstetric care for female CCS, which 
improves care and outcomes for CCS and their families. 




The aim of this research is to search for, evaluate and synthesise the existing 
data relating to live births of pregnant women who have received flank, 
abdominal or pelvic radiotherapy as treatment for childhood cancer. The 
findings will provide clinical and research recommendations based on the 
evidence to adequately inform both professionals and patients accessing 
maternity services with a history of childhood cancer. 
Table 1 - Aims of the review 
Title of the review: 
Female childhood cancer survivors and the impact of flank, abdominal or 
pelvic radiotherapy on live birth: A systematic review and meta-analysis 
Research questions: 
(1) What is the impact of flank, abdominal or pelvic radiotherapy for female 
           CCS on live birth outcome and associated adverse pregnancy      
           outcomes? 
(2) Are any associated adverse outcomes in pregnancy and childbirth  
           directly attributable to flank, abdominal or pelvic radiotherapy as a  
           child? 
Objectives: 
• To identify publications that investigate live birth and birth outcome of 
female CCS that have received radiotherapy to the flank, abdomen or 
pelvis as part of their treatment as a child  
• To critically appraise the methodological quality of publications  
• To synthesise data from identified publications to establish whether 
likelihood of live birth and adverse pregnancy outcomes are affected in 
this patient group and if this is attributable to their radiotherapy 
treatment as a child 
PICO  
P Childhood cancer survivors 
I Treatment for childhood cancer with radiotherapy to the flank, 
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           abdomen or pelvic region  
C General Population, siblings or non-exposed control group   
O  Live birth 
 
1.4  Outline of the review 
 
This systematic review compromises of six chapters. The PRISMA reporting 
guidelines for systematic reviews (Moher et al. 2009) have been used to 
structure and present the review and is included in Appendix 1. However, the 
researcher notes the use of the PPIE survey is a deviation from this guideline 
but is a novel element which strengthens the applicability of the findings.    
Chapter two explores PPIE in research, rationale for use in this review, methods 
and results. Chapter three discusses methodological underpinning of the 
researcher, the steps of the review, including search and selection processes, 
data management and synthesis. Chapter four presents the results of the 
review with summary tables, meta-analysis and narrative synthesis of additional 
outcomes and risk of bias assessment. Chapter five discusses the findings, the 
researcher’s personal learning, scope for further research bringing together 
methodological limitations, implications for practice and generalisability of 
findings. Chapter six concludes the discussion and will revisit the research 




Chapter 2 – Patient and Public Involvement and 
Engagement 
2.1  PPIE in maternity and health care 
 
PPIE in healthcare was introduced to provide a platform for patient opinion, 
experience and voice to be used as a valuable tool in shaping health care 
service provision (National Institute of Health Research (NIHR) 2012). It 
reinforces the ideology of making patients ‘partners’ in their care and is being 
prioritised by many health care trusts as an effective way to address key patient 
concerns through collaborative working (NIHR 2012). 
Likewise, PPIE in healthcare research is fast becoming the gold-standard 
approach to development of patient-centred projects and an integral part to 
funding applications (NIHR 2012). Cancer is a specialist area that has actively 
involved survivors, parents and people affected by cancer in their prioritisation 
of research priorities, project delivery and evaluation of services (e.g. National 
Cancer Research Institute (NCRI) 2013). Through this approach, long term 
effects of cancer treatment have emerged as an area of interest for survivors 
and parents, driving the agenda for future research and international 
collaborations such as PANCARE SURFUP (Gibson et al. 2005).  
Maternity services actively promote a patient and family centred approach to 
healthcare delivery, making women active partners in their birth choices, 
antenatal care and in accessing services throughout the peripartum period 
(NHS England 2016a:5).  However, the concept of PPIE in developing research 
priorities within maternity services is novel and relatively unexplored with only 
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one example of best practice in the UK (The London Maternity Strategic Clinical 
Network 2015). Despite the lack of PPIE driven research activity in UK 
maternity services, midwives have long been strong advocates for women 
during pregnancy and childbirth and are ideally placed to directly influence the 
research focus of multi-disciplinary projects and research priorities.  
The researcher has attempted to bridge this gap in clinical practice and has 
lead and developed a maternity based research involvement group called PIPR 
(Patients Involved in Pregnancy Research) which meets on a bi-monthly basis. 
The group have contributed to the research priorities in maternity research and 
been integral to research trial applications within the local trust. 
2.2  PPIE in this review  
 
The researcher has a strong background and appreciation for PPIE in research 
and healthcare provision and utilised the principles of INVOLVE and previous 
experience of delivery and participation in PPIE groups to adopt a patient-led 
approach to the alignment of the research outcomes with the use of an online 
PPIE survey.    
This is a rare feature in systematic reviews, which traditionally concentrate on 
data from existing sources and research questions and aims are researcher 
driven. However, clinical academic researchers are encouraged to prioritise the 
needs and views of the patients in their research to allow for faster translational 
impact into clinical practice (NIHR 2012). This is an approach supported by the 
James Lind Alliance, who set priorities for key areas of health care. They use a 
priority setting partnership model with multi-disciplinary and multi-stakeholder 
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groups to prioritise research questions which are of direct relevance and 
potential benefit to patients and the clinicians who treat them (James Lind 
Alliance 2018).  
“The idea of bringing together clinicians, patients and carers to discuss 
research priorities seems obvious – why shouldn’t all those affected have 
a chance to jointly discuss frustrations about the things we don’t know, 
and aspirations for the future?” 
(Ekkeshis 2018 (Quoted in James Lind Alliance 2018) 
The researcher was keen to incorporate past personal experience of being 
involved in PPIE initiatives into the design of the review. A PPIE survey was 
created to gauge survivor’s thoughts about the topic and the important issues 
they face as survivors of childhood cancer related to pregnancy, fertility and 
birth. The researcher wanted to align the outcomes selected for the review with 
the priorities of the survivors and involve PPIE groups into the plans for 
dissemination to ensure that full impact of findings can be shared with those 
who they affect.    
2.3  The PPIE Survey 
  
2.3.1 Aims and approach 
Table 2 - Aims of PPIE survey 
To verify justification of the review with CCS and their families 
To evaluate and reinforce the primary and secondary outcomes of the review 
To ensure the outcomes reflected the concerns and priorities identified by 
CCS and their families 
PPIE was not used to formulate the research question or selection of search 
terms as this had already been selected by the researcher using the PICO tool 
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and in the scoping review. The survey was also used to identify existing 
knowledge surrounding any possible implications for pregnancy and birth 
following radiotherapy and how this had been communicated to them.  
PPIE was aligned with the dissemination plan for the review, to allow wide 
communication of findings to all stakeholder groups including participants of the 
PPIE survey upon completion.   
2.3.2  Methods 
 
An online anonymous survey was sent to CCS (aged ≥16 years old), survivors 
who have had their own children and parents of survivors who have yet to have 
children. They were asked to complete a short survey to help identify and rank 
importance of a variety of selected outcomes used in this review. Qualtrics 
Survey tool was used to design the survey (Appendix 2) as a secure and easy 
to use format. Questions to assess background demographic information and a 
ranked question style were used and results subsequently compared to the 
selection of the primary and secondary outcomes used for the review.  
Participants for the PPIE survey were approached by the researcher using 
existing links to affected groups and social media platforms. Parent and survivor 
groups (My Kid has cancer support group, Wilms Tumour parents support 
group, Make September Gold for Childhood Cancer Awareness page, 
Childhood Cancer International Survivors Group, Twitter) and charity groups 
with access to parents of children with cancer (Childhood cancer and 
Leukaemia Group, Childhood Cancer Parents Alliance) were all approached. 
IRAS or NHS ethics was not required for this purpose and participation was 
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entirely voluntary, anonymous and participants had the option to withdraw at 
any time by emailing or telephoning the researcher within two weeks of 
participation. 
2.3.3  Results of the PPIE survey 
 
The PPIE survey used in this review was answered by 24 participants. Not all 
the questions were answered, however sufficient responses were given to 
support the outcomes used in this review.  
The background of the participants was primarily parents of children that have 
had cancer (19 out of 23) (Figure 4). Interestingly, three of the responses were 
from CCS that have already had a child. Only one participant failed to answer 
this question. Out of the 24 responses, 16 recorded that they or their child had 
received radiotherapy to the ‘tummy’ which was the lay term used by the 
researcher to encompass the target area of the review (Figure 5).  
In question four, 16 participants did not know the dosage of radiotherapy given 
and out of the seven that did or who selected ‘maybe’, only three could 
accurately record a figure (Gy) (Figure 6 and Table 3). This finding supports 
research by Green et al. (2010:2827) suggesting CCS and their parents do not 
remember or have accurate documentation of treatment dosages to be able to 
effectively answer patient reported outcome research questions.    
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Figure 4 - Q2 What is your background? 
 
Figure 5 -Q3 As part of your/your child's treatment, did you/they receive 
radiotherapy to the tummy? 
 




Table 3 - Q5 - If you do know how much radiotherapy was given, please write 
below (total Gy) 
If you do know how much radiotherapy was given, please write below (total Gy) 
28 sessions 
3600 
6 weeks daily doses 
64 




Only 18 responses were recorded for question six, which depicted an even 
spread of age of treatment between one to sixteen years old (Figure 7).  
Question seven related to awareness of any fertility issues due to cancer 
treatments as a child and 19 participants recorded that they had been told that 
‘definitely yes’ or ‘probably yes’ that they or their child would have implications 
for fertility (ability to have a baby) (Figure 8).  
Figure 7 - Q6 - If you/your child received radiotherapy to the tummy, at what 




Figure 8 - Q7 - Have you been told that your/your child's treatment for cancer is 
likely to affect fertility (ability to have a baby)? 
 
In question 8, the participants were asked to rank from most important to least 
important, what they would be concerned about during a pregnancy of a CCS 
that has had treatment including radiotherapy, the results ranked in Figure 9: 
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Figure 9 - PPIE rankings 
 
 





Pregnancy complications for mother
Abnormalities in the baby
Risk of the baby having cancer
7 (least important) 6 5 4 3 2 1 (most important)
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Figure 10 - Most important concern PPIE survey 
 
Figure 11 - Least important concern PPIE survey 
 
The remaining questions related to additional concerns not already asked and 
knowledge of information surrounding the issue (Table 4, Figure 12 and Figure 





































of paediatric oncology and survivorship and taken forward for potential future 
research projects to ensure that key issues are not overlooked.   
Table 4 - Q9 - Are there any other issues during pregnancy or birth that you 
think might be important? 




She will be trying ivf with egg donor. Unsure whether womb capable of carrying to full-
term. She has lung condition so needs further tests before to see if lungs and heart will 
cope. 
Strain on remaining kidney 
I got told I couldn't have children and a traumatic birth 
My daughter surviving pregnancy with one kidney and scarring of the abdomen 
Hormone issue while pregnant- she would have to conceive via in vitro- radiation ruined 
her ovaries. 
Emotional and psychological effect on mother 
 
Figure 12 - Q10 - Are you aware of any information given to survivors of 




Figure 13 - Q11 - If you/your child have been given such information, at what 
point were you given this? 
 
 
2.3.4  PPIE rankings – applicability to the review  
 
The results of the PPIE survey helped to validate the selected outcomes of the 
review. The three top-ranking concerns by CCS survivors, their parents or CCS 
that had been pregnant before were identified as: 
1. Pregnancy complications of the mother  
2. Miscarriage and abnormality in the baby 
3. Early labour  
The highest-ranking concern was ‘pregnancy complications for mother’ with 
‘abnormalities’ ‘miscarriage’ and ‘early labours’ being the next highest-ranking 
concerns. These outcomes have been included in the secondary outcomes of 
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the review, therefore reflection of the patient point of view and incorporating 
patient-verified outcomes into the review have been shown.   
The outcome of a live birth was not directly asked to participants, however 
relates to ‘A healthy baby’ which was ranked fourth in the survey. The outcome 
of a live birth is assumed as the intended outcome of all pregnancies. The 
researcher felt it was important to answer the question surrounding ‘a live birth’ 
and how this might be affected by radiotherapy treatment first and foremost, as 
this is what the desired outcome of pregnancy is. The selection of the primary 
outcome is further supported by the fact that live birth has not yet been 
addressed as a primary outcome in any research paper in this area.   
The additional questions provide an insight into possible future research 
projects, including how CCS and their families should be counselled to the 
potential odds of long term adverse effects on their health and consideration as 
to when this information is discussed.  
By placing PPIE into a systematic review design, the researcher has 
demonstrated how PPIE can be integrated into any research design and not 
simply large scale RCT’s. Dissemination of this patient-based approach will aim 
to raise awareness and encourage implementation of similar approaches in 
future research in this field. 
The next chapter, Chapter 3 will address the methodology and methods used to 




Chapter 3 – Methods 
3.1  Scoping review  
 
As part of the review, the researcher used a scoping review of the literature in 
the chosen topic area, based upon a framework by Arksey and O'Malley (2005). 
This was used to inform and refine the systematic review protocol and to avoid 
duplication of any existing review and ensure that sufficient evidence existed in 
this field of research to allow a systematic review methodological approach.  
Scoping reviews help identify appropriate parameters of a review (i.e. define the 
targeted population, intervention, comparison, outcomes- otherwise known as 
PICO) and explore terminology to be used in the research topic (Armstrong et 
al. 2011). Scoping reviews have a great utility for synthesizing research 
evidence and are often used to map existing literature (Armstrong et al. 2011). 
Therefore, they are of use when a body of literature has not yet been 
comprehensively reviewed or exhibits a heterogeneous nature such as in CCS 
and pregnancy outcomes.  
The research question and search terms used for the scoping review were: 
Table 5 - PICO for the scoping review 
P – Childhood cancer survivors  
I – Radiotherapy  
C – Nil 




Search terms were inputted into Medline and Cinahl databases. The results 
were collated, and abstract/titles were appraised by the researcher for 
relevance to the research question and quality appraisal by using the Critical 
Appraisal Skills Programme (CASP) checklists (CASP 2014), which the 
researcher was familiar with using.  
3.1.1  Findings from the scoping review  
 
The results from the scoping review provided 55,697 studies. Inclusion criteria 
were then applied that included: 
Table 6 - Inclusion criteria (scoping review) 
Studies from 2000 onwards  
Studies published in the English language 
In peer-reviewed journals  
Female childhood cancer survivors  
 
This produced 10 results, which verified that there were no randomised 
controlled trials (RCT’s), systematic reviews or UK/European clinical guidelines 
found for care of CCS treated with radiotherapy in pregnancy and birth. 
Similarly, no articles that addressed the needs of CCS when accessing obstetric 
healthcare in the UK were found. The studies identified were in the majority, 
retrospective cohort-studies based upon large registry data such as the British 
Childhood Cancer Survivorship Study (BCCSS) (Hawkins et al. 2008) and the 
American Childhood Cancer Survivorship study (CCSS) (Robison et. al 2009).  
The researcher discovered that the Scottish Intercollegiate Guidelines Network 
(SIGN) have produced one of the most comprehensive resources for CCS for 
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long-term health risks (Wallace, Thompson and Anderson 2013). They 
highlighted that pregnancy in a CCS is a risk factor for long-term adverse 
outcome and recommended that women who have had radiotherapy to an area 
which includes the uterus, should have pre-conception counselling and be 
supervised in a high risk obstetric unit (Wallace, Thompson and Anderson 
2013). However, this guideline is not specific to maternity service care provision 
or does not provide any detail as to the level of radiotherapy dosage needed to 
cause long-term effect.  
A resource from data in the CCSS was also discovered, which consisted of a 
table of outcomes and risks for pregnancy in relation to treatment and cancer 
type (St Jude Children’s Research Hospital 2017). Although this serves as an 
excellent reference tool, differences in population demographics, health care 
systems and access to health care in the UK and Europe means that 
applicability of these outcomes and attributed risks, would be limited in 
applicability or generalisability to the UK population.     
It was evident from the results of the scoping review that pregnancy outcomes 
of CCS were an important aspect of survivorship research. The scoping review 
revealed studies which suggested a link between childhood cancer treatment 
and pre-term labour, restricted intrauterine growth or low birth weight and 
stillbirth (Reulen et al. 2009: 2246, Wallace, Thompson and Anderson 2013:31, 
Green et al. 2009:2684). Evidence also pointed to abdominal radiotherapy 
received as treatment for childhood cancer as the most significant factor relating 
to adverse outcomes in pregnancy (Signorello et al. 2006, Reulen et al. 2017).  
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Chemotherapy use, and anthracycline exposure is well documented as having 
significant long-term risks for cardiovascular disease, heart failure and stroke for 
CCS (Armenian et al. 2015). Evidence suggests that there is a low risk of 
complications for women in pregnancy and birth if existing heart disease is not 
present before pregnancy and does not impact on live birth rates or outcomes 
(Armenian et al. 2015, Metzger et al. 2013).  
Also evident from the existing research, was the impact of childhood cancer 
treatment on male CCS and their partners.  Chow (2009), Green et al. (2003) 
and Signorello (2010) found no significant adverse effects in fertility or 
subsequent pregnancy for male CCS or their spouses, therefore, the 
justification for this review to focus on female CCS and radiotherapy as the 
main intervention was valid.   
3.2  Methodology 
 
3.2.1  Epistemology, Ontology and Paradigm of the research 
 
As the researcher is a midwife by background, it is important to acknowledge 
and consider any principles, beliefs or assumptions to limit bias and reliability of 
the research and to support or refute pre-defined conclusions of other 
researchers when appraising the project (Finlay and Gough 2008). 
Research into new cancer treatments and survival rates is traditionally viewed 
with a positivistic approach. The belief in a diagnosis, cause and effect, data 
collection, analysis and dissemination to inform which treatment arm or 
procedure is more effective for survival of patients is aggregative, and therefore 
suits a quantitative approach. Quantitative researchers believe that data will 
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confirm or refute a hypothesis, therefore answering a clinical problem, which 
could lead to improved outcomes for patients. Methodological designs such as 
interventional; RCT’s, Clinical Trial of Investigational Medicinal Product (CTIMP) 
and placebo designs are common and outcomes such as disease incidence, 
survival rates or event free time periods are often measured.  
In this systematic review, the researcher has adopted a positivistic 
epistemological standpoint, aligning with the paradigm that accepts knowledge 
and data to be trustworthy. In such a paradigm, knowledge in the form of an 
authoritative truth is derived from empirical evidence (Gordon 2016). A 
positivistic approach is appropriate to the research question of this review as 
‘knowledge’ in this instance, derives from empirical evidence collected by health 
care professionals regarding treatment outcomes of a patient set (CCS). This 
knowledge has been collated by the researcher with a quantitative and fact-
based approach to provide results which sit within this positivistic paradigm as 
the results are intended to be viewed with a belief that the data used is 
trustworthy and represents an overall outcome of a population (CCS) in relation 
to a treatment they have received as a child.  
3.2.2  Systematic review process   
 
There are many types of review, however, a systematic review is regarded as 
‘gold standard’ and is defined by its peer-reviewed protocol, ability to replicate, 
description of sources used, data synthesis, data extraction tools, meta-analysis 
(if appropriate) and strict inclusion and exclusion criteria and dissemination of 
results (Hemingway 2009).  Alternative reviews such as narrative reviews, 
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although providing a way to collate information can be open to bias and may not 
consider all the evidence to be able to generalise to the population. 
Systematic reviews aim to identify, evaluate and summarise the findings of 
available individual studies, providing evidence that is accessible, translatable 
and robust (Centre for Reviews and Dissemination 2009:3). This systematic 
follows the steps recommended by The Centre for Reviews and Dissemination 
(2009) and uses a PRISMA flow chart to chart search results (see Figure 15). 
The steps taken by the researcher are further detailed in Figure 14 below.  
A lack of a previous systematic review published or registered in female CCS 
and long-term effects of radiotherapy in pregnancy and birth, highlights the 
need for a systematic review to be undertaken. A systematic approach is the 
most appropriate and ‘gold-standard’ design methodology, to provide high 
quality research in this field and will ensure replicability, providing a resource 








Figure 14 - Steps to a systematic review  
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(Adapted from the University of Minnesota 2017, accessed on 1st February 2018)
 
3.2.3  The Research Question  
 
The PICO model (Population, Intervention, Comparator, Outcome) (Richardson 
et al. 1995) was used to define the research question, as it is a well-recognised 
tool for facilitating the search for clinically relevant evidence in the literature and 
recommended for reviews of interventions in health care. (Full and exhaustive 
PICO terms used for the database search can be found in Appendix 3). 
Table 7 - PICO for the review 
P Childhood cancer survivors 
I Treatment for childhood cancer with radiotherapy to the flank, abdomen or 
pelvic region  
C General population, siblings or non-exposed control group   
O  Live birth 
 
 
This led to the development of the following research question: 
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“With adult survivors of childhood cancer does radiotherapy to the flank, 
abdomen or pelvis effect term live birth rate?” 
This was then further developed to become the title of this review.  
3.2.4  Ethical approval  
 
Ethical approval was sought from Coventry University Ethics before 
commencement of the review. The application was approved on the 15th May 
2017 with the project number P46688. A further application was made on the 
18th July 2017 due to the nature of the PPIE survey used in the review, which 
was deemed as needing further approval. The second application was 
approved on the 4th August 2017 with the project number P60599. (Appendix 4).    
3.2.5  Protocol and registration  
 
This protocol for this review was registered on PROSPERO – The international 
prospective register of systematic reviews following ethical approval from 
Coventry University on the 30th May 2017 with the identification number 
CRD42017054533 (Appendix 5). The protocol was updated on PROSPERO on 
the 23rd March 2018 to reflect changes to the supervisory team and a change to 
the software programme used for data extraction. The review was marked as 








The search strategy was developed using PICO keywords and medical subject 
headings (MeSH) (title keywords given to published records). This included text 
words related to childhood cancer, childhood neoplasms, survivor, radiotherapy 
and pregnancy/birth. A draft MEDLINE strategy was produced and then 
adapted to the syntax and subject headings of the other databases and 
replicated (Appendix 6).  
The literature search was limited to the English language due to limited 
translation resources available. To ensure literature saturation, the reference 
lists of included studies were scanned and forward cited and back-referenced. 
Expert opinion was utilised, and any additional articles considered against the 
inclusion/exclusion criteria.  
A search of MEDLINE, PubMed, CINAHL, Google Scholar, Scopus, TRIP and 
ProQuest databases were searched for articles up until 30th September 2017. 
The researcher enabled alerts on the databases to include recently published 
studies from the commencement of the review until 31st October 2017. Any 
additional identified published studies were analysed against the inclusion 
criteria and results included if applicable. Google Scholar, due to having vast 
amounts of articles available was subjected to a pre-screen by the researcher to 
filter through only the results that fitted the research subject.    
The selection of databases was decided by the researcher to reflect the most 
accurate resources, likely to produce results in this field of research. This 
selection was confirmed as appropriate and extensive by subject librarians and 
the supervisory team.  
 
51 
3.3.1  Search terms 
 
Keywords, MESH headings and any additional search terms from the scoping 
review articles were added to the PICO list used for this review (Appendix 3). 
Keywords were expanded to include synonyms and alternative definitions for 
each term of reference. This allowed for differences in language, spelling, 
medical and lay terms and differences in keywords between databases, i.e. 
childhood cancer and childhood neoplasms.  
3.3.2  Eligibility criteria 
 
Inclusion and exclusion criteria for the studies were as follows (Table 8): 
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Table 8 - Inclusion and exclusion criteria 
 Inclusion Exclusion 
Population • Females aged >=16 years old 
• Females who have a history of 
being diagnosed with 
childhood cancer (up to age 
24) 
• Population for data will be 
restricted to recognised data 
registries from list of included 
countries  
• Men 
• Surrogates of survivors  
• Females treated for an adult specific 
cancer 
• Females treated for cancer during 
pregnancy or a birth <1yr from end of 
treatment  
• Females who have received fertility 
treatment or IVF to conceive a 
pregnancy 
 
Intervention • Radiotherapy to flank, 
abdomen and pelvis as part of 
a treatment plan for childhood 
cancer  
  
• Radiotherapy to other area including 
head/neck/extremities etc. 
• Exclusive surgery as treatment   
• Exclusive chemotherapy as treatment   
• Exclusive immunotherapy or proton 
beam therapy as treatment  
 
Comparator • General population control  
• Sibling control  
• Non-exposed control 
(non-exposure relates to 
radiotherapy) 
 
• Nil  
Outcome Primary –  
• Live birth at term (defined 
as 37 weeks of completed 
pregnancy) 
Secondary –  
• Pregnancy Outcome (Live 
birth, miscarriage, 
stillbirth, neonatal death 
up to 28 days and 
intrauterine death)  
• Premature birth (24 weeks 
to 36+6 weeks gestation)  
• Growth restriction (birth 
weight below 2.5kgs or 
below 10th centile of 
predicted growth 
projection) 
• Caesarean section rate 
(elective or emergency) 
• Onset of labour type 
(spontaneous, induced or 
augmented) 
• Absence of any of the outcomes listed 
in the inclusion criteria 
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• Uterine dysfunction 









• USA, Australia, Canada and 
EU countries 
 
• Non-EU countries  
• Other countries not identified as being 
in the inclusion criteria  
 
Design  • Case-control/Cohort studies  
• Quantitative methodology 
 
 
• Qualitative methodology 
• Grounded theory  
• Ethnography  
• Narrative  
• Phenomenological  
• Case Study 
• Thematic analysis  
• Interpretative phenomenological 
analysis (IPA) 
• Mixed methodology  
• Systematic reviews or reviews 
Literature • Published articles in peer-
reviewed journals  
 
• Unpublished articles 
• Conference presentations 
• Poster presentations  
• Expert opinion 
• Case studies of less than 10 
participants   
  
Language • English 
 
• Non-English 
Follow-up • Any follow-up period 
 
• Nil  
 
 
3.3.3  Data management 
 
RefWorks was used as the primary software for exporting the documents from 
the databases to the EPPI Reviewer4 software in RIS format. Duplicates were 
not removed upon exportation to RefWorks as this was undertaken following 
export to EPPI Reviewer4.  
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RefWorks is a widely recognised software programme for research and suitable 
for secure data management. EPPI Reviewer4 software is a recognised 
software programme used by the Cochrane Collaborative and is password 
protected. The software choices allowed for restrictive access to articles and 
review stages to ensure data extraction, screening and meta-analysis were kept 
confidential and secure. Both RefWorks and EPPI Reviewer4 allowed checking 
and removing of duplicates and exportation of references into suitable formats 
that can be used for future publications. 
3.3.4  Selection process 
 
The screening process for studies was carried out electronically using EPPI 
Reviewer4 as per inclusion/exclusion criteria: 
Table 9 - Review selection stages 
Stage 1: Title and abstract screening for inclusion criteria (first reviewer) 
Stage 2: Full-text documents in PDF form obtained and uploaded (first reviewer) 
Stage 3: Full-text screening against inclusion criteria (first reviewer) 
Stage 4: Review and agreement of a random selection of title/abstract papers (10% 
of total included) and all full-text included studies (second reviewer)  
 
Full text PDF versions were obtained for all studies included for full text 
screening. Records that were not available via the ATHENS gateway or 
Coventry University gateways were obtained by the researcher via the local 
trust library ordering system. The PDF versions were then uploaded to EPPI 
Reviewer4.   
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Discrepancies in screening for title/abstract and full text stage were discussed 
between reviewers and a consensus was reached. Although a plan to include a 
third independent reviewer was made, this was not necessary to resolve any 
discrepancies. Authors of papers were contacted by the researcher if there was 
insufficient or unclear detail reported in the publication and if no response was 
received within two weeks, the articles were excluded from the review. All 
screening decisions were recorded and accounted for and study selection 
reported as per PRISMA flow diagram guidance (Moher et al. 2009) (Figure 15). 
3.4  Data Analysis plan  
 
3.4.1  Data extraction  
 
EPPI Reviewer4 was used to extract data from the included studies alongside a 
Microsoft Excel data sheet to record key patient demographics and outcomes. 
The Microsoft Excel sheet was needed as an additional resource to the 
software, to assist with an easy visual reference data source for the researcher 
and second reviewer as the software did not provide an easy to use example of 
this.  
Data extraction headings were created by using a modified Cochrane data 
extraction template (Appendix 7) and subsequently inputted into EPPI 
Reviewer4 software to record features such as cancer type, treatment and 
dose, age at treatment, ethnic background, and age at pregnancy, adverse 
events and other key data.   
Crude binary data were then extracted from the individual studies for outcomes 
by the first reviewer using a 2x2 contingency table. If crude data could not be 
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found in the paper, then the authors were contacted to provide this information. 
If this could not be provided within two weeks or the author did not respond in 
this time, then the study was not used for meta-analysis. Data from the binary 
tables were then transferred to the EPPI Reviewer4 software for meta-analysis 
following calculation of odds ratio for each outcome.  
Odds ratios (see glossary) were selected as the most appropriate measure for 
the review due to a more symmetrical representation of the outcome definition, 
i.e. the odds ratio for outcome Y is the inverse of the odds ratio for the outcome 
not Y and is representational of each outcome without the need for amending to 
suit clinical applicability, i.e. applies to premature labour, miscarriage, live birth 
equally. Risk ratios lack this symmetry, therefore necessitating adjustments to 
present one risk ratio for outcome Y and another for outcome not Y. However, 
the researcher accepts that by using odds ratios and not relative risk or risk 
ratios, then it can be more difficult to translate risk in clinical practice as the ‘risk’ 
of an event happening is traditionally discussed in comparison to ‘odds’ of an 
event happening. This is usually regardless of the measurement for data used 
in the original research, despite the clear mathematical differences in 
calculation. 
3.4.2  Synthesis of results  
 
Measures of outcomes from studies were recorded and tabulated and feasibility 
of meta-analysis considered. To accurately test for statistical heterogeneity, a 
chi-squared test (also known as χ²) was used with an I² test used to confirm 
results and ensure rigour of findings. Parameters of I² of > 50% and a chi-
squared p value of <0.05 were used to identify significant heterogeneity as 
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recognised standard measures within statistical analysis. A plan for narrative 
review was made for outcomes deemed too heterogeneous and sub-group 
analysis was planned for but was not undertaken due to limitation of available 
studies and heterogeneity in and between included studies. Narrative synthesis 
was used to summarise and explain the results of each study, quality of the 
evidence and the relationship of the findings between the included studies.  
The narrative review was based upon guidance from Cochrane (Ryan 2013), 
however did not follow this specific framework. The researcher believed that this 
approach to presenting key elements of the review combined with the added 
benefit of applicability to clinical practice demonstrated a more rounded view to 
the narrative synthesis of findings not applicable for meta-analysis.  
3.4.3  Assessment for meta-analysis 
 
Meta-analysis is intended to use statistical methods to summarise the results of 
combined studies. Data is analysed for strength and consistency of the 
evidence and investigate reasons for any inconsistencies. The two most 
common statistical models for meta-analysis are the fixed-effect model and the 
random effects model (Borenstein et al. 2010:97) 
The fixed-effects model represents a one true effect size encompassing all the 
studies in the analysis. Any differences in effects are presumed to be due to 
sampling error and the data derives from one population rather than multiple 
variable populations. A choice of model should reflect the sampling frame and 
not the test for heterogeneity used (Borenstein et al. 2010:98).   
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In contrast, the random-effects model follows the belief that true effect size 
might differ from study to study due to variables in population demographics. 
Random effects models reflect data where all or some of the model parameters 
are considered as random variables. In this review the researcher chose to use 
a random effects model for analysis and chose the headings of ‘binary odds’ to 
represent the type of data included by studies and to reflect the variety of 
geographical locations and population variances in the data.  
Assessment and suitability of the included papers for meta-analysis was made 
by the researcher and confirmed by the second reviewer. An initial 
consideration of clinical homogeneity was undertaken by the researcher with 
guidance from the supervisory team, by deciding if there were not more than 
three of the same outcomes from included studies that matched a control group 
(sibling, general population or non-exposed CCS), then meta-analysis would not 
be possible to do with the software.  
Following this assessment, EPPI Reviewer4 software was used to run the meta-
analysis for the following outcomes of: 
Table 10 - Meta-analysis outcomes 
Live birth (non-exposed CCS and sibling) 
Miscarriage (non-exposed CCS) 
Pre-mature birth (non-exposed CCS) 
Stillbirth (non-exposed CCS) 
 
The researcher was assisted by supervisory team to assess for final inclusion 
based upon the outcome of statistical pre-defined heterogeneity markers and by 
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assessment of a forest plot visualisation to determine if the overlap was in 
favour of effect or non-effect of the intervention (radiotherapy to the flank, 
abdomen or pelvis). Once meta-analysis was completed, if there were multiple 
outliers, the spread was too broad or not to one side of the scale, significant 
statistical heterogeneity was considered likely.  
3.4.4  Quality appraisal 
 
Quality of the studies and their risk of bias were assessed at the individual study 
level using a quality index suitable for cohort or case-control studies. For this 
review, the Newcastle Ottawa Scale was used as a recognised and reputable 
tool for health care research appraisal of non-randomised studies (Appendix 8). 
Following data extraction and synthesis, the recommended scoring system was 
used to categorise studies, with the most robust achieving up to nine stars. 
They were then classified as ‘good’ ‘fair’ or ‘poor’ quality reflecting selection, 
comparability and outcome classifications.  
Low quality studies can lead to a distortion of the summary effect estimate and 
it remains a challenge for researchers to find a tool which can critically assess 
cohort and case-control designs effectively. The NOS is star-based visual tool 
which works in a similar way to Grade (Guyatt et al. 2008), to give a quick 
overview of the study for the researcher. The tool used for this review was the 
cohort study template (Appendix 8).  




Table 11 - Systematic bias in the review 
• Using Cochrane guidance of the steps to a systematic review 
• Registering the review on PROSPERO  
• The use of an independent reviewer to assess and analyse studies included 
in the review   
• The use of an independent reviewer to second check data extraction and risk 
of bias  
• The use of EPPI Reviewer4 software in the review and meta-analysis 
 
Reporting bias, an important consideration for systematic reviews, was 
addressed by the researcher in the following ways: 
Table 12 - Reporting bias in the review 
• All outcomes recorded and tabulated 
• Meta-analysis of results and sensitivity analysis considered although high 
likelihood of extreme heterogeneity  
• Use of EPPI Reviewer4 to show all tabulated results 
• Limitations of the review discussed  
• Conflict of interest of the authors made transparent 
• Rationale for the approach and methodology used for the review clear 
• Absence of data or any outcomes that were looked for but were not reported 
by included studies will be reported 
• Non-significant results discussed  
• Clear plan for dissemination identified by the researcher 
 
3.4.5  Allocation of roles 
  
The second independent reviewer confirmed/disputed inclusion of papers for 
title and abstract screening. As recommended in systematic review process 
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(Centre for Reviews and Dissemination 2009), a random sample of 10 percent 
of the entire selection was provided to the second reviewer.  
The Data collection and extraction process was completed by the first reviewer 
independently. The second reviewer (external to the supervisory team) then 
confirmed validity of the data and agreed consensus on all included papers. Any 
discrepancies were discussed and although planned for, a third independent 
reviewer was not required for arbitration. 
3.5  Protocol amendments 
 
During the review, amendments were noted from the original protocol. These 
are identified as follows (Table 13): 
 
Table 13 - Protocol amendments 
• The inclusion criteria published on PROSPERO stated, “Population for 
dataset will be restricted to participants of the British Childhood Cancer 
Survivorship Study”. This was changed to “Population for dataset will be 
restricted to data from a recognised data registry from the list of included 
countries” as the researcher accepted that papers would be published 
outside of the UK/United States of America (USA) and would use alternative 
data registries 
• Exclusion criteria defined as “Radiotherapy to head/neck/extremities i.e. legs” 
was amended to ‘Radiotherapy to other areas’ to assist clarity for screening 
purposes for first and second reviewer 
• Comparator was amended from “nil” to include general population, siblings or 
non-exposed control group to allow meta-analysis of data 
• Inclusion criteria for studies were amended to exclude systematic reviews 
and reviews as it was felt that these publications did not provide original raw 
data. It was also decided that case studies would not be included as this 




• The supervisory team was amended during the review; however, this did not 
affect the researcher’s role or the role of the secondary reviewer 
• Software choices of Revman and RefWorks as detailed in the protocol were 
changed to EPPI Reviewer4 software programme 
 
3.6  Time management and costs 
  
Costs for the review can be found in Appendix 9. The researcher has conducted 
the review and meta-analysis as part of a Health Education England (HEE) and 
NIHR funded Masters by Research Programme at Coventry University. Funding 
to attend national and international conferences through the Global 
Researchers Programme at the home institution to support plans for 
dissemination and impact of the results were also planned for.  
The review has followed a time planned approach by use of a Gantt chart 
(Appendix 10), which was amended during the programme.   
3.7  Dissemination and impact 
  
Dissemination for the review is intended with publication in peer-reviewed 
publications and journals and via conference and poster submissions. Outputs 
will be promoted on social media platforms and the review will be made public 
on Research Gate, Research Fish and to the NIHR. Pre-existing links with 
specialists in the field will be maintained and the results from the review shared 
amongst interested parties/collaborators for future projects and specialists in 
this area.  The review will also be published on PROSPERO. A lay summary, 
produced in conjunction with PPIE and CCS/parent groups will be disseminated 
to local, national and international stakeholders and groups that have an 
interest in long-term effects and survivorship issues. Contact will also be made 
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with the midwifery organisations RCM, NMC and RCOG to ensure that results 
are widely and appropriately disseminated, allowing for clinical impact and 
awareness of the public. 
3.8 Summary 
  
Following the scoping review and construction of the research question, a clear 
and focussed protocol was published on PROSPERO which enabled a robust 
systematic review to be undertaken by the researcher. The results of the review 




Chapter 4 – Results  
4.1  Introduction 
 
This chapter will present the results of the review, including meta-analysis 
where data could be extracted, narrative synthesis and an outline to the 
characteristics and methodological approach of the included papers. 
Applicability and clinical impact of the results for key findings is also described. 
4.2  Results of search 
 
A search of MEDLINE, PubMed, CINAHL, Google Scholar, Scopus, TRIP and 
ProQuest databases for published records up until 30th September 2017 in the 
week commencing 14th August 2017. This returned a total of 1495 records 
taken forward for the screening stage of the review. The PRISMA flow diagram 












The diagram shows 51 records were located from other sources. These sources 
included references and citations from forward citing and back referencing, 
records used in the scoping review and studies forwarded from specialists in the 
PRISMA 2009 Flow Diagram 
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field of long term CCS survivorship research with whom the researcher had 
existing links.  
Duplicate checking found 257 records. Despite this step another 30 records 
were excluded at the title and abstract screening stage due to being duplicates. 
The researcher was unable to identify why they had been missed in the original 
scanning action and could not correct the error by adding them manually. After 
contacting the software owners, the researcher created an exclusion category 
‘duplicates’ to ensure the records were accounted for.       
Features which lead to exclusion by the researcher were: 
Table 14 - Exclusion features (Screening and abstract stage) 
Two records written in another language other than English 
Two records originating from a country not in the inclusion criteria (India and 
South America) 
64 records did not fit the inclusion criteria for study design, e.g. conference 
papers or qualitative methodology 
47 records excluded for treatment modality (chemotherapy treatment only or 
records that reported on populations where treatment modality could not be 
separated or established) 
1118 excluded for relevance to the PICO and research area (e.g. treatment 
for breast cancer, male CCS and biology focused records) 
 
This left 26 records taken forward for full text screening. At the full-text 
screening stage the following records were excluded:  
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Table 15 - Exclusion features (full text stage) 
Seven records due to study design (e.g. abstract from conference proceedings or 
opinion piece) 
Four, due to target population (e.g. male and female CCS data unable to be 
extrapolated or from a data source that was not a recognised registry) 
Four, due to treatment modality (radiotherapy was not given or not able to be 
separated from other data) 
 
This left 11 records for data extraction and risk of bias assessment. 
The second reviewer agreed that records taken forward for full text review met 
the criteria for the inclusion/exclusion restrictions. There were no 
disagreements. The second reviewer was then allocated the 26 full text records 
to review for inclusion into the data extraction stage. There were no 
disagreements at this stage for inclusion and exclusion although two records 
were marked by the researcher as ‘unsure’ to include as male/female data 
could not be separated easily, the second reviewer agreed that this should be 
excluded in line with the exclusion criteria of the review. 
Data were extracted using modified Cochrane data extraction template 
(Appendix 7) headings for the 11 remaining records. Then studies were 
appraised using the NOS for case-control or cohort studies (Appendix 8). Two 
records contained data that could not be extracted due to usage of percentages 
or odds ratio/risk ratio (OR/RR) without raw data. The authors of the studies 
were contacted by the researcher to provide raw data to be used for meta-
analysis, however one author replied to say that he could not access the data 
any longer and no response was recorded from the other author after two 
weeks, therefore excluded as per the protocol.   
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The second reviewer was asked to confirm two records for accuracy of data 
extraction and risk of bias assessment. The second reviewer also confirmed if 
two records identified as unsuitable for meta-analysis should be included in the 
narrative synthesis of the review. The decision was made to include these in the 
final review but not in the meta-analysis as they fitted the inclusion criteria. This 
left nine records suitable for meta-analysis.    
The final included studies were (Table 16): 
Table 16 - Included studies 
Chiarelli et al. 2000 Green et al. 2002 
Green et al. 2010 Reulen et al. 2017 
Lie Fong et al. 2010 Signorello et al. 2006 
Reulen et al. 2009 Signorello et al. 2010 
Winther et al. 2008 Haggar et al. 2014 (not used for meta-
analysis) 




4.2.1  Outcomes 
 
Outcomes from the included studies have been tabulated below (Table 17) 




Table 17 - Primary and secondary outcomes from review 
 
Chiarelli et al. 2000 
Perinatal death OR 4.8 Live birth OR 0.85 
Low birth weight OR 8.09 Congenital abnormality OR 2.38 
Miscarriage OR 0.85  
Green et. al 2002 
Sibling control 
Live birth OR 0.53 Stillbirth OR 1.26 
Miscarriage OR 1.43 Abortion OR 1.54 
Low birth weight OR 2.64  
Non-exposed CCS control 
Live birth OR 0.91 Miscarriage OR 1.48 
Stillbirth OR 1.27 Abortion OR 1.1 
Green et. al 2010 
Congenital abnormality OR 1.06 Live birth OR 2.78 
Hypertension OR 3.6 Premature labour OR 3.16 
Malposition OR 4.06 Obstructed labour OR 1.96 
Abnormality of force OR 1.29 Cord complications OR 2.34 
Premature birth OR 3.58 PROM OR 1  
Reulen et al. 2017 
Hypertension (pre-existing and not) 0.33 Caesarean (emergency and elective) OR 
0.16 
Live birth OR 0.29 Gestational Diabetes OR 0.36 
Anaemia OR 0.21 Growth issues OR 0.14 
Post-term OR 0.11 Labour complications OR 0.06 
PROM OR 0.09 Malpresentation OR 0.13 
 Haemorrhage OR 0.15 
Lie Fong et al. 2010 
Congenital abnormality OR 4.67 Low birth weight -1.07 (SMD) 
Pre-eclampsia OR 17.07 Manual removal of placenta OR 6.71 
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The primary outcome, live birth, showed eight studies which reported this as an 
outcome. Odds ratios have been presented as crude numerical data and not 
been adjusted for confounders. Therefore, there are slight variations in the odds 
ratios recorded by the authors of the studies.  
4.2.2  Summary tables 
 
In addition to Table 17, a more detailed summary table including study 
demographic characteristics and outcomes can be found below. The researcher 
found it necessary to have a separate Microsoft Excel spreadsheet outside of 
the software to have a visual reference for the results as it was felt that the 
software did not produce this effectively.  
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4.3  Meta-analysis 
 
Following assessment for suitability of meta-analysis, EPPI Reviewer4 software 
was used to conduct the meta-analysis with selection of parameter outputs by 
the researcher. Outcome type was selected as ‘binary: odds ratio’, model 
selection was ‘DL (DerSimonian-Laird estimator), significance level was set to 
95 and 4 decimal places selected. Confidence intervals and forest plot/funnel 
plot selections were made which produced the reports for five outcomes: 
Table 19 - Meta-analysis report categories 
Pre-term labour (control non-exposed CCS group) 
Stillbirth (control non-exposed CCS group) 
Live birth (control non-exposed CCS group) 
Live birth (control sibling group) 
Miscarriage (control non-exposed CCS group) 
 
Out of the five meta-analysis reports, three did not meet the criteria for 
heterogeneity as described in the review protocol (I² result of >50% or χ² result 
with a p value significance of <0.05). Two of the meta-analysis reports, pre-term 
birth and stillbirth met the criteria and was classed as a significant result. 
Overall odds ratio of having a pre-term birth when exposed to radiotherapy to 
the flank, abdomen or pelvic area as a child was 3.27 (95% CI 2.71-3.96) with 
an I² result of 0% and a p value χ² result of 0. 0.7633. The odds of having a 
stillbirth was 1.62 (95% CI1.10-2.40) with and I² result of 0% and p value χ² 
result of 0.5943. Full reports from the meta-analysis have been provided in 
Appendix 11. Summaries are included below:  
 
78 





















4.3.1  Characteristics of included articles 
 
The included studies included in the review were retrospective cohort studies. 
The studies utilised established data registries to obtain information, such as 
the BCCSS and the CCSS. Several studies used medical records to 
corroborate data provided from patients, however some information was 
missing.  
The included studies were published in peer-reviewed journals, funded with a 
mixture of academic institutional support and public health grants. Conflict of 
interest was not declared by any of the included studies; however, five studies 
did not refer to any conflicts within the text. The age of the participants was not 
easily found as many authors did not report on the age of the participant upon 
analysis of the outcomes, however, there was assurance in the 
inclusion/exclusion criteria and description of the population of the studies that 
the CCS was post-treatment of at least one to five years and that they were 
diagnosed in line with the inclusion criteria of the review <24 years.  
All original data registry information and citations were checked by the 
researcher for verification as some authors based their studies on cohorts which 
are described elsewhere, e.g. BCCSS, CCSS, and WTLTFU. The included 
studies varied in population size from less than 1000 to more than 34000. 
Sampling techniques were purposeful and convenience with some studies 
choosing data linkage techniques to reduce population and sampling bias.  
In one study (Green et al. 2010) it was not clear as to the diagnosis age of the 
CCS to confirm eligibility of the study for inclusion into the review. The author 
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was contacted by the researcher to confirm that in the patient group used for 
the study, all CCS were diagnosed before age 24 years. The author confirmed 
this and provided evidence for the cohort used, this allowed inclusion of the 
study into the review.  
4.3.2  Characteristics of excluded studies 
 
Excluded studies featured patient groups that could not be separated from 
either their treatment regime or that included collective male and female CCS in 
the outcome data. Many studies were not relevant to the subject area and 
included studies of females who had cancer whilst pregnant and fertility or 
Artificial reproductive treatment (ART) topic focus.  
Several excluded studies were found to be conference abstracts, opinion pieces 
or book chapters upon further investigation and were therefore excluded. One 
study (Sudour et. al 2010) was excluded at the full text stage of the screening 
process as the data used did not come from a recognised data registry as 
specified in the inclusion criteria. The study used hospital records from two state 
hospitals in France and did not feature a control group. Although 
methodologically sound, the exclusion criteria for this review states that the data 
must derive from a recognised resource. France has an existing national 
childhood cancer registry from which data could have been collated or 
extracted, however the author did not choose to do this. 
Additional features of exclusion included one systematic review, older studies 
which reported on outcomes but were then superseded by another study using 
the same data after a period (updated studies were included) and studies where 
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treatment with radiotherapy to the flank, abdomen or pelvis could not be 
separated from other areas of the body.       
4.3.3  Methodological features of the studies  
 
The included studies were longitudinal retrospective cohort studies. This is the 
most appropriate design for patient reported and data registry outcomes of this 
kind as prospective data would prove difficult in terms of length of study and 
recruitment.  
All the included studies used data which had previously been collected by 
patient reported outcome and hospital treatment records. Consent had been 
given for future research of this kind by the patients upon recruitment to the 
registry data study. Therefore, consent was not needed from patients to access 
their data and treatment history for follow on studies. Chiarelli et. al (2000) 
recorded their consent process as primary care physicians were approached to 
consent to sending of information to eligible patients. 
Eligibility of the population was confirmed in the exclusion/inclusion criteria of 
the studies; however, some authors directed the reader to additional data 
sources such as BCCSS, CCSS to provide further data. All studies used 
recognised statistical tests and/or software packages to analyse and synthesise 
data and all but two (Haggar et al. 2014 and Winther et al. 2008) of the studies 
had clear population demographical data of the affected group and accounted 




4.3.4  Control groups  
 
All studies included in the final review had a comparator control group. They 
were categorised as: 
Table 20 - Control group categories 
General population (non-cancer match) 
Sibling control  
CCS who did not receive radiotherapy (non-exposed CCS)  
 
This was to ensure outcome data related to the same type of control. Green et 
al. 2002, Winther et al. 2008 and Reulen et al. 2009, provided data for two 
different categories of control (sibling match and general population); therefore, 
data were recorded for both groups on the data extraction tool.  
Sample sizes were of average size and ranged from <1000-3000+ and included 
a variety of convenience, purposeful (sibling matches) and random (data 
linkage comparisons from data registry) sampling methods were utilised.  
Of the included studies, five studies provided data for exposed versus non-
exposed groups and six provided data for the general population or sibling 
matches. Mueller et al. (2009) and Haggar et al. (2014), despite providing data 
from the general population comparison groups, could not be taken forward for 
meta-analysis of data provided due to data extraction problems. 
Demographical data were provided for the control group from three authors and 
the controls were age matched to their affected CCS in three studies. 
Socioeconomic considerations and parity was recorded by two authors. Type of 
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cancer, treatment type and age at diagnosis was extracted by the researcher 
from the studies. Apart from Chiarelli et al. (2000), all authors provided this 
information. Chiarelli et al. (2000), failed to record the type of cancer of the CCS 
in the paper.  
4.3.5  Risk of bias  
 
The included studies were assessed for risk of bias based upon the Newcastle 
Ottawa Scale. The ROB results of the studies including the allocation of ‘good’ 
‘fair’ or ‘poor’ quality is presented in Appendix 12. Of the included studies, ten 
were classed as ‘good’ quality and one study classed as ‘poor’ quality (Chiarelli 
et al. 2000). Out of the studies included in the meta-analysis eight studies were 
classed as ‘good’ and one classed as ‘poor’.  
The researcher made the decision to include the study ranked as ‘poor quality’ 
(Chiarelli et al. 2000) as the results produced were not reliant on this study for 
statistical significance. No weighting of studies was used in the analysis and 
although ranked as ‘poor’ quality, the paper was of sound methodological 
quality and fitted the inclusion criteria of the review. However, the researcher 
accepts that this is a limitation or threat to validity as combining studies of poor 
quality with more rigorous studies may not be useful for recommendations and 
create a false sense of precision around the truth (Garg, Hackam and Tonelli 
2008). 
In relation to reporting bias within the findings, there is a risk due to exclusion of 
unpublished or studies which did not meet the criteria of this review. These 
studies may hold key data that could be influential to results or that contradicts 
 
88 
results of this review. However, since this is the first systematic review in this 
area, the researcher does acknowledge this, but is confident that results found 
are from evidence based and reliable sources subjected to stringent inclusion 
criteria which is essential for transferability and formulation of clinical 
recommendations.   
There is also a possibility of reporting bias in the results of the studies, with 
authors choosing to report on the most significant adverse outcomes and not 
secondary outcomes nor wider clinical data that could be influence and impact 
upon maternal and child health, e.g. only one author looked into pre-eclampsia, 
haemorrhage, gestational diabetes or socioeconomic factors such as maternal 
age at delivery (Reulen et al. 2009, Reulen et al. 2017). 
4.4  Narrative synthesis 
 
How narrative syntheses are carried out varies widely, and historically there has 
been a lack of consensus as to the constituent elements of the approach or the 
conditions for establishing credibility (Centre for Reviews and Dissemination 
2009). Cochrane advises authors to attempt a narrative synthesis that includes 
investigation of the similarities and the differences between the findings of 
different studies, as well as exploration of patterns in the data. This might 
involve examining links between study outcomes and any other factors related 
to the study design and conduct (Ryan 2013). 
Findings from individual studies have been collated to represent outcomes to 
demonstrate trends of data that would benefit from further research. These 
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outcomes could not be taken forward due to heterogeneity of control group and 
classification of outcomes and have been tabulated below: 
Table 21 - Common trends narrative synthesis 
Congenital abnormality 
Chiarelli et al. 2000 OR 2.38 No increase in congenital 
abnormality 
Green et al. 2010  OR 1.06 No trend  
Low birth weight (LBW) infant 
Chiarelli et al. 2000  OR 8.09 CCS more likely LBW infant 
Green et al. 2002  OR 2.64 Radiotherapy CCS more likely 
to have LBW 
Green et al. 2010 Not calculated Increase in LBW increased in 
RT CCS 
Lie Fong et al. 2010  -1.07 (SMD) Normal birthweight after 
adjustment for age of CCS 
babies 
Signorello et al. 2006  Uterus OR 2.35 
Ovary OR 1.81 
Cumulative OR 
2.11 
Radiotherapy CCS increased 
risk of LBW 
Reulen et al. 2009   OR 3.42 RT CCS increased LBW 
Neonatal death 
Chiarelli et al. 2000 OR 4.81 Radiotherapy CCS more likely 
to have neonatal death  
Signorello et al. 2010  OR 1.86 Radiotherapy increased risk of 
neonatal death. 
Maternal complications 
Green et al. 2010 Hypertension OR 3.6 
Malposition OR 4.06 






Abnormality of force OR 
1.29 
PROM OR 1 
increasing radiation 
dose 
Reulen et al. 2017  
 
Hypertension OR 0.33 
GDM OR 0.36 
Anaemia OR 0.21 
Post-term pregnancy OR 
0.11 
labour complications OR 
0.06 
PROM OR 0.09 




Hemorrhage OR 0.15 
3-fold increase in 
hypertension, 
increased risk of 
GDM, anaemia, 
caesarean section for 
CCS who receive 
radiotherapy  




Pre-eclampsia OR 17.07 
Haemorrhage OR 9.16 





not different  




The above findings corroborate existing evidence from authors who suggest 
that CCS who receive radiotherapy are at risk of a variety of maternal 
complications during pregnancy and birth and neonatal death, low birth weight 
infants (Reulen et al. 2009: 2246, Wallace, Thompson and Anderson 2013:31, 
Green et al. 2009:2684). It also supports evidence that congenital abnormalities 
and genetic effects upon the baby after birth are not linked to childhood cancer 
treatments (Winther et al. 2009, Boice et al. 2003).  
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In relation to reporting of the primary outcome of this review, the likelihood of 
live birth or an effect on live birth rates in the included studies did not feature as 
a primary outcome in any but was discussed by authors within the discussion 
part of the studies. This would suggest that further research surrounding live 
births of female CCS is warranted and that it is an area of interest for 
researchers and clinicians in this field. 
4.5  Applicability to clinical practice 
 
4.5.1  Radiotherapy delivery and toxicity 
 
Loss of fertility is a key issue for younger cancer survivors (Teh et al. 2014:1). 
Direct irradiation of the ovaries is known to induce ovarian failure in up to 90 
percent of women and ovarian treatment thresholds have been well 
documented with protective treatments such as transposition, shielding, or 
transplantation offered to try and reduce the risk of radiation-induced ovarian 
damage (Future Fertility Trust 2018). However, the efficacy of such 
interventions is variable (Revelli 2007). 
Little evidence exists to investigate treatment toxicity thresholds of the uterus as 
an organ, unlike their ovarian counterparts and implications of dosages and 
relation to age at delivery is unknown. Larsen et al. (2004) suggested that a 
direct high dose radiation (>25 Gy) to the uterus in children commonly leads to 
irreversible damage to both vasculature and muscular function. Sudour et al. 
(2014) suggests that a dose of below 4Gy appears to be the threshold dose, 
depending on the associated treatment plan. However, even low doses may 
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affect future fertility and pregnancy sustainability, but research to support or 
refute these claims is not apparent (Sudour et al. 2014).  
Teh et al. (2014) also agrees that the threshold radiation dose for uterine 
damage to occur such that pregnancy is not sustainable is unknown and alludes 
to the suggestion that younger age at uterine radiation leads to greater adverse 
effects on uterine reproductive capacity, particularly in pre-pubertal girls. This is 
corroborated by Reulen et. al 2009, Revelli et al. 2007, Sudour et al. 2010 who 
infer that radiation doses of >25Gy directly to the uterus in childhood appears to 
induce irreversible damage, however research is so limited in this area that 
conclusions cannot be carried forward to clinical practice.  
An example of a childhood malignancy that receives direct uterine radiotherapy 
is Wilms tumour. The table below illustrates treatment doses related to stage 
(Adapted from Saunders 2015). 
Table 22 - Radiotherapy treatment dose for Wilms Tumour 
 
This example suggests that children treated for Wilms tumour would receive on 
average close to the 25 Gy marker that is suggested to cause irreversible 
damage, yet no known communication of this damage, awareness or organ 
Stage II high risk flank RT: 25.2Gy with a boost of 10.8Gy 
for extensive residual disease 
Stage III intermediate risk flank RT: 14.4Gy with a boost of 10.8Gy 
for extensive residual disease 
Stage III high risk flank RT: 25.2Gy with an extensive 
residual disease boost 10.8Gy 
Diffuse intraperitoneal. Spread/major rupture whole abdomen 20Gy 
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protection for the uterus in childhood cancer radiotherapy planning exists. 
Therefore, female CCS and their families are not aware of any potential 
damage that could be caused from their or their child’s treatment, which is 
unacceptable and demands closer consideration so that families are fully 
informed of long-term treatment related effects.   
Paediatric radiotherapists and paediatric oncologists involved in treatment 
planning, should be aware of the long-term effects to the uterus caused by 
radiotherapy and communicate these to CCS and the long-term follow up team. 
Considerations to protect the uterus at the time of delivery or a more precise 
method of delivery which does not adversely affect reoccurrence or survival 
could be introduced to protect long-term pregnancy adverse outcomes. 
4.5.2  Pregnancy rates of CCS and live birth 
 
Pregnancy rates of CCS, have been found to be less than the general 
population and in sibling comparator groups by Reulen et al. (2009:2245). This 
provides insight into the non-significant result for the primary outcome of live 
birth in this review. If the pregnancy rates themselves are reduced in an already 
small population, then the effect size may be too small to accurately predict or 
measure an effect or non-effect. This is often known as a type II reporting error 
where a non-effect may be found, but this is due to bias within the data and the 
population size (Lieberman and Cunningham 2009) 
Reporting bias is an important factor to results and relates to the under-
reporting or non-reporting of all outcomes as authors favour to report outcomes 
which show adverse effect. Live birth would be a positive outcome for a CCS, 
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therefore it would not be considered as a reportable outcome for assessment of 
effect on adverse outcome. In the papers included in the review, although live 
birth was measured in eight of them, the researcher did encounter difficulty in 
extracting data for live birth. This suggests that more longitudinal prospective 
design research project is needed investigating this outcome with adequately 
powered sample sizes to determine exact effect or non-effect.  
4.5.3  Pre-term birth 
  
A pre-term birth occurs before the 37th week of pregnancy and carries an 
incidence rate of 60,000 per year in the UK. The UK has a pre-term birth rate of 
7-8% of all pregnancies, higher than most European counterparts (Tommy’s 
2018a). Pre-term infants are at an increased risk of long-term illness, disability 
and death which directly correlates to the gestation at which they are born. 
Some pre-term births are planned due to pregnancy complications (iatrogenic), 
however the rate of pre-term birth from spontaneous pre-term labour is an issue 
for health care providers in the UK.  
Prevention of pre-term birth is defined as one of the key strategic priorities in 
obstetrics and carries great economic and health care implications for health 
care services in the UK (NICE 2015:2). The best intervention for the prevention 
of pre-term birth is still unclear despite vast research in this area to try and 
attempt to answer the question as to what causes pre-term birth (World Health 
Organisation 2018).  
Risk stratification is key to ensure that woman at an increased risk of pre-term 
birth are referred for high-risk obstetric care and receive a detailed pregnancy 
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plan including screening and interventional planning to avoid a pre-term birth. 
Pre-term birth carries significant maternal and fetal mortality and morbidity risk, 
with the costs of caring for pre-term infants reaching approximately one billion 
pounds per year in England and Wales (Tommy’s 2018a). Tests such as the 
‘fetal fibronectin’ test have assisted with the prediction if pre-term labour and 
birth are likely to occur in the next 24 hours. However, obstetric professionals, 
researchers and health care professionals still do not know what causes pre-
term labour (Tommy’s 2018a). 
Table 23 - Current risk factors for pre-term birth 
(Adapted from NICE 2015) 
Clinical History  Imaging  
History of mid-trimester loss  Short cervix <25mm on transvaginal 
ultrasound  
PPROM in previous pregnancy Cervical funnelling  
Previous pre-term birth  
History of cervical treatment for cervical 
intraepithelial neoplasia  
 
Multiple births   
 
NICE, the leading body for health care guidelines, recommends identification of 
women at risk of pre-term labour, surveillance and intervention to ensure 
optimal outcomes (NICE 2015). Treatment with radiotherapy or a history of 
childhood cancer is not featured in this list, nor is a broader patient history of 
cancer treatment. This is a gap in risk stratification highlighted by the significant 
results of this review that could adversely affect the outcomes for both mother 
and baby with this patient history if not addressed and recognised.   
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4.5.4  Stillbirth 
 
When a baby dies after 24 weeks of pregnancy it is defined as a stillbirth. 
Before this gestation it is called a late miscarriage or miscarriage. Some authors 
also report this outcome as ‘spontaneous abortion’. In the UK there are 3,430 
stillbirths each year which equates to nine per day (Tommy’s 2018b). Like pre-
term birth, often the cause is unknown, however risk factors exist, and health 
care professionals seek to identify and raise awareness of the risks of stillbirth 
to prevent and increase surveillance during pregnancy. The highest population 
attributed risk factor associated with stillbirth is fetal growth restriction (Gardosi 
2013). Although fetal growth restriction was not identified as a significant result 
in this review, perhaps due to reporting and classification variances and non-
measurement of this outcome preventing meta-analysis. Stillbirth however, was 
found to be at increased odds for female CCS who have been treated with 
radiotherapy to the flank, abdomen or pelvic areas as children, therefore 
assessment of growth restriction is an important variable that needs to be 
considered in future research.  
Saving Babies’ Lives (NHS England 2016b) is a care bundle aimed at health 
care professionals to enable a reduction in stillbirths in the UK and highlights 
the issue as a priority for the NHS. An algorithm was produced to detail risk 
factors for pregnancies with classifications of ‘low’ and ‘high’ risk (Appendix 13). 
This guidance does not include any information relating to prior treatment as a 
child with radiotherapy for cancer or even a broader history of cancer before 
pregnancy. This again illustrates that the results of this review can be used to 
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highlight and acknowledge a significant impact upon neonatal health of a patient 
group which has not been acknowledged previously.     
4.6  Relevance to research question 
  
The research questions asked in this review are:  
(1) What is the impact of flank, abdominal or pelvic radiotherapy for female 
CCS on live birth outcome and associated adverse pregnancy 
outcomes? 
(2) Are any associated adverse outcomes in pregnancy and childbirth 
directly attributable to flank, abdominal or pelvic radiotherapy as a child? 
From the results of the systematic review, a significant result to suggest impact 
on likelihood of live birth for CCS treated with radiotherapy to the flank, 
abdomen or pelvic regions could not be found. However, due to heterogeneous 
results, non-reporting of the primary outcome or inability to extract raw data, a 
conclusion that this is not a significant factor for CCS cannot be justified.  
A statistically significant result linking risk of pre-term birth to radiotherapy 
treatment as a child to the flank, abdomen and pelvic regions with an odds ratio 
of 3.27 (95% CI 2.71-3.96) was found, which supports previous studies by 
Reulen et al. (2017), Green et al. (2010) and Signorello et al. (2006). Equally a 
significant result was found linking stillbirth to this patient group with an odds 
ratio of 1.62 (95% CI1.10-2.40) supporting previous research by Signorello et al. 
2010. This demonstrates that female CCS who have received radiotherapy to 
the flank, abdomen and pelvic regions are at increased odds of adverse 
outcomes in pregnancy. This finding warrants further research into additional 
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adverse effects and a clinical need for interventional planning by obstetric 
professionals and paediatric oncologists to ensure optimal care and outcome for 
this patient group. 
4.7 Summary 
 
This chapter has presented the results of the systematic review, meta-analysis 
in the context of the characteristics, metalogical rigour and the applicability to 
both radiotherapy and pregnancy care. 
Chapter five will draw together the results of the review alongside personal 
learning, the impact of PPIE in the review and provide a synthesised information 
resource with research and practice recommendations.  
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Chapter 5 – Discussion  
5.1  Introduction 
 
This chapter will draw together the learning process from undertaking this 
review in three key areas. Firstly, personal learning and development of the 
researcher (which will be documented in the first person), secondly additional 
validity and insight gained through PPIE work from Chapter 2, and finally, the 
empirical new knowledge drawn from the results of the systematic review 
including reliability and limitations. Findings will be placed in context within 
existing knowledge and followed by clinical practice implications and 



























Figure 21 - Levels of knowledge 
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5.2.1  Reflection on learning  
(Based on Gibbs 1988) 
5.2.1.1  Description 
  
During the Masters by Research programme, I have continued to work as a 
clinical research midwife, which has been challenging to manage two frames of 
mind and dedicate time to each discipline. The knowledge gained through my 
clinical role of 10 years, has provided a unique perspective for me when 
commencing a programme of study for clinical academic research.    
Prior to this programme of study, I completed the Interdisciplinary Non-medical 
Clinical Academic Programme (INCA). This provided an excellent foundation to 
the distinct differences of working as a clinical academic and the importance of 
remaining clinically focused to accelerate the impact of results into clinical 
practice for the benefit of patients.   
The opportunity provided during the programme to take part in specialist 
workshops, conferences, training days and spending time with experts in the 
field of the relevant subject area, was fundamental to the development of this 
review. I was also able to sound out ideas and discuss how to incorporate my 
personal experience in patient and public involvement groups into this 
systematic review design, something which hadn’t been attempted before.  
 
5.2.1.2  Feelings 
  
The apprehension of a ‘non-medic’ undertaking this type of research and 
actively working to be a recognised professional in this field was great. I had 
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countless reservations about the research area and topic being too ‘niche’ to 
have clinical impact. Despite this, peer and colleague validation and increasing 
publications in this area encouraged and motivated me to move forward and 
continued reassurance that the topic was relevant, would have clinical impact 
and that it was important not only to clinicians but also to CCS and their families 
really helped to cement my motivation and passion to complete the project.   
Self-directed learning and time management proved difficult to navigate at first, 
with revisions of Gannt charts and setbacks with new learning needed for the 
EPPI4 Reviewer software programme. However, by using a needs-based 
analysis and with regular supervisory support and guidance, this ensured the 
project as completed on time. The home institution study peer group also 
created a passionate and focused environment, which helped me to develop a 
positive and determined mind-set, which was necessary for independent study.  
As the project progressed, my confidence to engage in informed conversations 
with other academics and the ability to explain and defend my results grew. This 
also developed into colleague discussions and learning sessions about the 
importance of research in clinical practice with presentations in mandatory 
training days and journal club.   
 
 
5.2.1.3  Evaluation 
 
My clinical academic journey has represented an evolving circular process of 
building upon prior learning, adding in new learning and then reflection on what 
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I had achieved. A pictorial representation of this process has been represented 
in Figure 23. 




Upon completion of the course, 
personal reflection enabled a 
retrospective look on the journey, the 
progress in learning and development 
achieved and a realisation of how far I 
had progressed.    
At the start of the programme, a steep learning 
curve commenced as training began. This 
started with acknowledging prior learning and 
came back around full circle to learning the 
basics again with research modules, university 
workshops, research specific training and 
development of clinical portfolios 
After the first year, there were up’s and 
downs which included putting together the 
pieces of the project, obtaining ethical 
approvals, literature searching, software 
issues and statistical analysis new learning. 
This caused confidence to waver but then it 
grew thanks to support and guidance.  
Upon completion, personal reflection enabled 
a retrospective look on the journey, the 
progress in learning and development 
achieved and a realisation of how far I had 
progressed from the start of the course. 
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5.2.1.4  Conclusion 
  
Through completion of the programme and personal development as a midwife, 
I have felt that my journey into the clinical academic world has been 
commenced and future aspirations will include the opportunity to develop, lead 
and facilitate research which helps to really change the way healthcare is 
practised. I plan to continue academic studies alongside clinical practice and 
seek new opportunities to further clinical academic ability and experience.   
Dissemination and raising awareness around my results and keeping close 
collaboration with professionals in this field of research will be continued. This 
will aim to assist new learning, pave the way for further research collaborations 
and assist the translation of new evidence into clinical practice, improving 
patient outcomes.  
5.2.1.5  Action Plan 
 
Table 24 - Action plan for learning and development 
• Complete dissemination and impact plan to ensure results from 
research are translated   
• Submit abstracts, posters and publications to disseminate 
results   
• Work alongside clinical colleagues and maintain links with 
professional groups   
• Work with obstetric colleagues to increase awareness of results 
and discuss future projects to improve patient care 
• Apply for future funding to enable continued study and develop 
clinical academic career pathway  
5.3  PPIE voices 
 




Including PPIE in the review was a novel approach, as it is often never included 
in a systematic review as outlined in Chapter 2. Limitations to the PPIE activity 
and the level of involvement exist, which could be improved if this approach 
were to be replicated. PPIE is advised from initiation of idea through to 
dissemination and impact of results (NIHR 2012). The researcher 
acknowledges that PPIE could have been used in the design of the research 
question and the selection of the outcomes, rather than the justification or 
alignment of them with the PPIE priorities. Also, PPIE could be incorporated into 
the review activities, for example using a lay member to help select and extract 
data from texts and confirm eligibility. PPIE could also be incorporated into the 
writing of the results and the creation of the abstract to ensure clarity, readability 
and patient need is reflected.  
Barriers to this level of engagement included time frame and funding for the 
project. Learning from the PPIE went beyond the framing of the systematic 
review and the researcher would recommend exploration of this via further PPIE 
in future work to align with the ethos of INVOLVE (NIHR 2012) and James Lind 






5.4  Empirical review findings 
 




As presented in Chapter 4, this systematic review provided a statistically 
significant link between pre-term birth (birth occurring before 37 completed 
weeks of pregnancy) in pregnancies of female CCS treated with radiotherapy to 
the flank, abdomen or pelvic area (odds ratio 3.27, 95% CI 2.71-3.96). The odds 
of having a stillbirth were also significant with an odds ratio of 1.62 (95% 
CI1.10-2.40). Although not a primary outcome of the review, this result carries 
huge clinical impact for patients, babies and healthcare providers.   
In the primary outcome of impact on live birth rate, data could be analysed by 
meta-analysis in both the CCS versus non-exposed CCS control group and the 
CCS versus sibling comparator group. However, the results were not deemed 
suitable for inclusion due to heterogeneity. Equally, likelihood of live birth for 
female CCS versus sibling controls found that the odds ratio favoured a non-
effect. Despite this result, the heterogeneity was assessed to be significant, 
therefore could not be used as a conclusive result for the review.  
Low birth weight, although identified as a significant result authors of studies 
included in the review, could not be analysed as an outcome using meta-
analysis due to lack of comparable studies with this outcome. However, more 
research with the same control group comparator and standardised terminology 
and categorisation is needed to achieve this might produce an alternative 
finding. 
Data from included studies suggested significant links to maternal complications 
during pregnancy such as haemorrhage, miscarriage and pre-eclampsia and is 
suggested by the researcher as an area that would benefit from further 
research. Maternal complications carry significant maternal morbidity and 
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mortality and notable fits within the top ranked PPIE concern about ‘pregnancy 
complications in the mother’ (See 2.3.4) 
5.5  Strength of evidence 
 
5.5.1  Systematic Process 
 
The systematic review was conducted in accordance within recommended 
practices (Centre for Reviews and Dissemination 2009) and meets PRISMA 
recommended guidelines (Moher et al. 2009). Ethical approval was attained, 
and an independent reviewer used for screening and selection of texts. 
Recognised software (EPPI Reviewer4) and statistical software programmes 
were used, and secure data management employed by the researcher 
(RefWorks).  
A pre-defined research protocol was submitted to PROSPERO before 
commencement of the review and the review updated as completed. Meta-
analysis results were measured against heterogeneity measures to ensure that 
any significant results were comparable to evidence-based reporting 
parameters of acceptance. Results were identified and presented, and a 
dissemination and impact plan outlined by the researcher. 
A recognised risk of bias assessment tool (NOS) was used to appraise the 
included studies and all findings tabulated and presented within the review.  
5.5.2  Reliability of the evidence 
  
As the included studies for this review are cohort studies, the applicability and 
‘quality’ of the evidence may be criticised by some researchers and is 
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acknowledged by the researcher. Due to the existence of no randomised control 
trials (RCT’s) in this field, a systematic review of cohort studies might be viewed 
negatively in the respect of applicability, rigour and hierarchical importance of 
the results, which typically favours RCT’s, systematic reviews of RCTs, or RCTs 
with a very low risk of bias (Bowling 2014:203).  
Despite this, cohort study methodology is the most appropriate design in this 
rare disease type. Constraints with obtaining adequate sample size, 
comparators and ensuring children are provided with the most effective 
treatment to cure their cancer is of upmost importance and prevents a 
randomised control trial design.  
5.6  Discussion of limitations 
 
Limitations to research are important to acknowledge for transparency of the 
research, contextualisation of the results, assessing the validity of the research 
and assigning credibility of the research team.   
5.6.1  Limitations of the data  
  
Although 11 studies were obtained in this review, there is a notable limitation of 
available evidence in this field. There is also acknowledgement from the authors 
of the included studies that some of the data, vital to the results, is missing due 
to inability to obtain accurate treatment modality and dosage information.  
The data also relies heavily on self-reported data outcomes, which produces 
adequate sample sizes for research, however, longitudinal cohort studies are 
often criticised due to the potential for significant recall bias of participants (e.g. 
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participants in many registries were asked to recall information about 
miscarriages and pregnancies). Chow et. al (2016:575) highlights that self-
reported data might not be the most representative and could lead to significant 
loss of data.  
Furthermore, the data used in most of the studies derives from the BCCSS and 
CCSS. Despite this extensive and reliable resource, it does not reflect recent 
novel drug and immunotherapy developments and risk stratification methods 
allowing for toxicity reducing treatments or high- risk pathways based upon 
genetic and biological information now used in modern practice.  
Patient cohorts used in these registries were relatively young when they were 
approached; therefore, perhaps limited numbers of participants would have 
reached an age where reproduction was likely, and many more participants may 
have data available now which has not been analysed. The data analysed in the 
studies is more than ten years old, which could be deemed non-representative 
of the true cohort of patients now completing treatment. 
5.6.2  Software limitations 
  
The software used by the researcher to assist with the data management and 
conducting of the review (EPPI Reviewer4) required new learning and 
familiarisation of processes by the researcher. This impacted upon the time 
management of the review and led to difficulties when attempting to allocate 
screening and full text allocations and removing duplicates. It also required an 
additional purchase to allow access by the second reviewer, which was 
unforeseen at the commencement of the review. The researcher soon became 
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familiar with the format and sought assistance with the software providers which 
allowed for successful completion of the review.   
5.6.3  Analysis of data 
  
Meta-analysis could be conducted in five outcomes within the review. 
Significant results which satisfied the heterogeneity markers were found in pre-
term birth and stillbirth. The other outcomes did not satisfy the heterogeneity 
measures; however, the results can be used to strengthen findings from 
independent studies suggesting that live birth of female CCS exposed to 
radiotherapy to the flank, abdomen and pelvis as children is affected (Reulen et 
al. 2017) and that miscarriage is an area of research that requires further 
analysis, especially as this was identified in the PPIE survey as the second 
most important outcome for pregnancy of female CCS (Appendix 2) 
Limitations within the review from data extraction and analysis were 
acknowledged by the researcher as more sophisticated statistical packages 
were not used due to timeframe or cost restrictions. Therefore, raw data were 
used for extraction and odds ratios calculated without the ability to adjust for 
cofounders or adjust for sociodemographic variables. Also, two studies were not 
able to be used for meta-analysis due to the availability of data, which may have 
impacted upon the results of the review. 
The researcher also acknowledges that there is a limitation in the results found 
due to a possible type II reporting error, with non-significant findings of live birth 
both in the CCS versus sibling and non-exposed comparator groups. The data 
extracted for the studies relies upon accurate data collection, adjustment of 
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variables and adequate population size to power the study and it is of note that 
none of the included studies in this review were powered to capture live birth as 
a primary outcome.  
If the sample size is not adequate to demonstrate an effect, then the results 
cannot be confidently upheld. Some studies were also not able to be included in 
the meta-analysis due to missing data, which in turn may have influenced the 
results. The reliance on self-reported data and non-reporting of events such as 
miscarriage could also be a key variable, as people may have perceived early 
pregnancy events or minor ailments as being classed as insignificant by others, 
or distressing to report, which may bias data collected. This may impact the live 
birth rate effect, as with more accuracy through outcome validation, or with 
increased sample sizes and statistical powering for live birth as a primary 
outcome, it is possible an effect may have been seen, or if the non-effect 
continued to be observed there would be more confidence in its reliability.   
5.6.4  Heterogeneity of data 
 
The included studies demonstrated heterogeneity within and across studies, 
which impacts upon clinical recommendations and synthesis of data, e.g. three 
out of the five meta-analysis reports were deemed too heterogeneous to be 
classified as a significant result.  
Likelihood of live birth for female CCS versus non-exposed CCS provided an 
odds ratio of 0.90 (95% CI 0.44-1.86). This suggests that likelihood of live birth 
is neither effected nor non-effected by prior treatment with radiotherapy to the 
areas mentioned due to wide distribution and significant heterogeneity between 
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papers. Heterogeneity was found to be (I² of 98.54% and χ² p value of < .0001) 
which implies that authors reported and measured this outcome with such 
variation that more research would be needed to be conclusive in this 
assumption. 
In likelihood of live birth for female CCS versus sibling comparators an odds 
ratio of 0.74 (95% CI 0.59-0.94) was found. This suggests that live birth is less 
likely in female CCS. However, the heterogeneity measure revealed an I² value 
of 84.12% and χ² p value of 0.0018, determining that the result cannot be 
conclusive. More studies would be needed with measurement of this outcome 
to determine true effect or non-effect. 
5.7  Similar research ongoing in this field  
 
As mentioned in chapter one, (see 1.1.4), There are currently no systematic 
reviews with the same research question as this review. There have been 
various attempts to collate evidence from international studies investigating 
pregnancy outcomes of CCS (Van Dorp et al. 2018, Shliakhtsitsava et al. 2017, 
Kalapurakal et al. 2004, and Nagarajan et al. 2005). However, authors have not 
used a recognised systematic methodology or have provided any specific 
clinical recommendations for health care professionals providing maternity care 
to CCS. Data have also been reliant on self-reported outcomes, with 
acknowledgment of missing data for treatment modality and dosage within 
studies (Van Dorp et al. 2018, Nagarajan et al. 2005).  
Shliakhtsitsava et al. 2017 published a systematic review into pregnancy 
outcomes of paediatric and young adult leukaemia survivors and highlighted 
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gaps in research for CCS, specifically for sub-populations at the highest risks of 
adverse perinatal outcomes. The review, although investigating key outcomes 
for CCS such as likelihood of live birth and pregnancy complications, did not 
contain treatment modality data that were extractable, therefore it was difficult to 
establish if and adverse outcome was related to either chemotherapy, 
radiotherapy or surgery. It also failed to distinguish CCS data from their 
population who had been diagnosed before age 24. The review also focuses on 
chemotherapy toxicity of treatment and maternal cardiopulmonary risk in 
pregnancy, therefore does not conflict with this review and was excluded by the 
researcher.  
A review by Van Dorp et al. (2018) (published after the literature search of this 
review and therefore not included), investigated the reproductive outcomes of 
female cancer survivors. The review was not registered, nor did it provide 
replicable systematic methodology. However, the findings are of importance 
and reported that female CCS who maintain fertility had an overall pregnancy 
relative risk of 0.67 to 0.81 and live birth rates lower than the general public 
(hazard ratio, 0.79 to 0.82). The authors supported findings from previous 
research that suggest pregnancy in CCS may be associated with risks to both 
the mother and the fetus such as miscarriage and preterm birth and advised 
that women at risk of complications in pregnancy require preconception 
assessment and counseling from both obstetricians and oncology providers. 
Notably, there is also a gap in this research from the patient or CCS voice.   
Future work of interest to the researcher, includes an international 
harmonization guideline project investigating the obstetric care needs of CCS in 
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pregnancy and birth. Work is ongoing and unpublished; however, the 
researcher is a member of the working group and will disseminate results of this 
review to contribute to the guideline and will consider results in relation to 
applicability to the UK health care system once published.  
The researcher also acknowledges a systematic review registration on 
PROSPERO from Australia entitled “Reproductive outcomes in female 
childhood cancer survivors”. This review is not completed or published and aims 
to investigate wider effects of both chemotherapy and radiotherapy in 
pregnancy and birth of female CCS, therefore not specifically replicating the 
review in this thesis.   
A notable consideration for future research in this field is the rapid 
advancements in medical technology and expertise. Radiotherapy techniques 
and new therapies such as IMRT and Proton beam radiotherapy (The Christie 
NHS Trust 2018) are constantly evolving and improving, which may change the 
impact that radiotherapy may have on long term likelihood of adverse 
pregnancy and birth outcome. Green et al. (2009) agreed by suggesting that 
future research should consider newer chemotherapeutic agents and should 
evaluate risk for genetic disease of offspring of CCS. Edgar and Wallace (2007) 
also highlighted that prospective cohorts treated with contemporary therapies 
are needed to determine actual risk for CCS in pregnancy.  
5.8  Contextualisation of results 
  
Results of the review carry significant clinical implications and health care 
economic considerations. Pre-term birth and stillbirth have been identified by 
the NHS as key priorities in health care for pregnant women (NICE 2015). 
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Health care costs related to a pre-mature baby cost the NHS millions per year 
and the psychological distress and associated maternal morbidity rates caused 
by pre-term birth and stillbirth carry multi-factorial consequences for mothers 
including birth trauma, susceptibility to infection, perineal trauma and 
depression (Tommy’s 2018a). 
Communication of adverse outcomes or late-effects is paramount to ensure that 
children affected by cancer and their families are aware of risk and benefit 
before consenting to clinical procedures. Health care professionals involved in 
the immediate treatment of childhood cancer and long-term care of CCS, have 
a responsibility to be aware of potential short and long-term complications and 
communicate this to health care professionals and CCS and their families. A 
call for clearer threshold for toxicities of organs such as the uterus should also 
be made to ensure that practitioners responsible for delivering the treatment are 
aware of the long and short-term effects to organs in the field of radiotherapy.  
Obstetrics and midwifery care planning needs to balance clinical need and 
patient preference and satisfaction to provide optimal outcomes and to maintain 
the woman-centred care approach. If health care professionals are not 
adequately informed of increased odds of an adverse outcome or the need for 
additional surveillance, then this puts at risk the health of the mother and the 
baby.  
5.9  Future research and recommendations 
 
Recommendations for future research and clinically focused recommendations 
arising from the included studies of the review include: 
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Table 25 - Research recommendations from the review 
• A generic need for more longitudinal research and research into education of 
CCS and their families surrounding fertility and pregnancy likelihood after 
treatment 
• Investigation into transition of care between the Paediatric and the adult care 
services as it is an important factor to the communication of long-term effects 
and appropriate care including surveillance for co-morbidities  
• Exploration of geographical variances in service provision and uptake of long-
term follow up services by CCS and TYA’s 
• Investigation into long-term health outcomes of children born to CCS. It has 
been suggested that possible mutagenic effects of cancer treatment could 
predispose children of CCS to congenital abnormalities or even cancer itself. 
(Although notably this was ranked as a low priority concern for CCS 
responding to the survey presented in Chapter 2. If further research identified 
a link, then this priority could change) 
• Investigation into whether any additional clinical impact exists when fertility 
preservation techniques are used in CCS to conceive. Assisted-reproduction 
techniques (ART) such as IVF already carries increased risk during 
pregnancy and there may be scope to investigate if this existing risk is further 
heightened by having a background of childhood cancer treatment.  
• Fetal exposure to medications, regardless of previous treatment exposures 
has been linked to a risk of cancer in offspring and further highlights the need 
for research into long-term outcomes of offspring in current medical trials in a 
pregnant population (Hoover et al. 2011) 
 
Research by Kelly and Levine (2017) highlighted the inadequate high-risk 
referral rate of CCS for obstetric care. They found that pregnancies of female 
CCS treated with abdominal radiotherapy, were not correctly identified as high-
risk pregnancies needing greater supervision and suggested that health care 
systems are not uniform in their approach in correctly identifying CCS in need of 
referral to high-risk maternal-fetal medicine programmes (Kelly and Levine 
 
116 
2017). Therefore, the researcher has highlighted key areas for research that are 
applicable to clinical practice: 
Table 26 - Clinical recommendations from the review 
• Review of current radiotherapy practice as very little is known surrounding 
maximum and minimum treatment thresholds for the uterus. Organ sparing 
measures, longitudinal prospective studies of CCS who have been exposed 
to radiotherapy in the uterine region and developing more targeted 
treatments considering the findings of this review are areas where health 
care professionals delivering childhood cancer treatments could improve the 
care they provide to children with cancer and have direct patient impact. 
• Exploration of how information should be communicated to CCS (in relation 
to the odds of having an adverse event in pregnancy and birth directly 
attributable to radiotherapy as a child). Information regarding who is best 
placed to communicate this information, where and when, could translate 
into improved high-risk referral rates and improved patient care and 
outcomes.  This was highlighted within the PPIE survey in Chapter 2 and 
supported by Edgar and Wallace (2007:1893) who recommended that more 
communication should be given to CCS about the impact of their treatment 
on fertility and pregnancy/birth outcomes. The researcher aims to consider 
and take these recommendations forward with future research projects.   
• Exploration of medical interventions during pregnancy and childbirth in this 
patient set that might improve outcomes based upon supporting evidence. 
For example, Revelli et al. (2007) suggested that female CCS should be 
monitored for myometrial thickness and features of abnormal placentation at 





Chapter 6 – Conclusion  
6.1  Research aims and question 
 
The aim of this review was to search, evaluate and synthesise existing data 
relating to live births of pregnant women who have received flank, abdominal or 
pelvic radiotherapy as treatment for childhood cancer. This has been achieved 
with the completion of a systematic review and meta-analysis and the provision 
of a synthesised information resource. 
The research questions proposed by the researcher were: 
(1) What is the impact of flank, abdominal or pelvic radiotherapy on female 
CCS on live birth and associated adverse pregnancy outcomes? 
(2) Are any associated adverse outcomes in pregnancy and childbirth 
directly attributable to flank, abdominal or pelvic radiotherapy as a child? 
This systematic review has provided statistically significant results to 
demonstrate that there is an increased odds of pre-term birth and still birth for 
CCS in pregnancy and birth and that this is directly attributable to cancer 
treatment as a child (0-24 years) with radiotherapy to the flank, abdomen or 
pelvis.  
The impact upon live birth for female CCS treated with radiotherapy to the flank, 
abdomen and pelvis were inconclusive with more research, comparable 




6.2  Impact and dissemination plan 
  
Upon completion of the masters’ course, the researcher intends to continue 
further studies. The researcher intends to apply for PhD study either with an 
academic institution or via the NIHR clinical academic pathway to build upon 
and address key gaps identified within this review. They would also like to 
develop leadership skills and further understanding of research methods that 
are unfamiliar and statistical packages and health economics experience.  
The researcher intends to disseminate results from the review within the clinical 
area and the wider paediatric oncology and obstetric communities. They will 
work to publish results in key publications and apply to present the work at 
conference and events in this field of research. They will also aim to publish a 
lay-summary of the results and share this with PPIE groups and parent and 
survivor communities to widen the impact of the results. The researcher also 
aims to showcase research findings at key meetings in the childhood cancer 
long-term effects arena.  
Connections that have been made throughout the programme with the 
supervisory team, mentors and specialists in the field will prove to be key 
resources for developing and furthering the research journey and the 
researcher hopes to include and share with them key developments and 
successes.  
The main measure of impact and dissemination for this review is to educate, 
raise awareness and instigate change in the care of female childhood cancer 
survivors who become pregnant, so that they are aware of the likelihood of any 
adverse outcome and so that professionals involved in their care can advise, 
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plan and intervene based upon evidence-based resource. This will in turn 
optimise outcomes and provide a tailor-made care approach for CCS.    
6.3  Final conclusions to review 
  
The population of adults in society that have a history of childhood cancer is 
growing by 1,300 per year (Children with Cancer UK 2018). Studies have 
identified that female CCS are at an increased risk of complications during 
pregnancy and childbirth, a risk directly attributable to treatment for childhood 
cancer (Signorello et al. 2006, Reulen et al. 2017, Mueller et al. 2009). 
Treatment for childhood cancer with radiotherapy has been identified as the 
most significant risk for adverse outcomes in pregnancy and birth, particularly 
when received to the flank, abdomen and pelvic areas (Reulen et al. 2017).   
A systematic review of the evidence investigating the impact of radiotherapy to 
the flank, abdomen or pelvis on live birth outcome for female CCS was 
conducted. The purpose of this review and its results was to provide a 
synthesised information resource for researchers and professionals, based on 
evidence which has been subject to a systematic methodology and risk of bias 
assessment addressing the long-term implications for pregnancy and birth 
outcome of CCS.  
PPIE was used to help shape and reinforce the selected outcomes of the review 
with the use of an online survey. The results of which were considered by the 
researcher throughout the review process, ensuring a patient-focused 
approach. PPIE was integrated into the dissemination plan of the review, to 
ensure wide-scale dissemination of results to all stakeholders, with the aim to 
have maximum applicability and impact upon clinical practice.   
 
120 
Female CCS that have received radiotherapy to the flank, abdomen or pelvis 
are at a significantly increased odds of pre-term birth (odds ratio 3.27, 95% CI 
2.71-3.96) and stillbirth (odds ratio 1.62, 95% CI1.10-2.40) in pregnancy. A lack 
of effect for the impact of live birth rate could not be verified due to a lack of 
data, equally in relation to additional adverse pregnancy outcomes suggests 
that more research is needed in this area to confidently define impact or effect.  
The increased odds of a premature birth and stillbirth in this review demonstrate 
that health care professionals involved in the obstetric care of female CCS, 
should ensure that a high-risk pregnancy care plan is in place and that an early 
referral to an obstetric team is made. Clinicians should also consider the 
evidence from this review and supporting publications in relation to surveillance 
and interventional measures for pre-term birth and stillbirth. Interventions such 
as early pregnancy surveillance, serial ultrasound scanning, cervical length 
assessment and early induction of labour are pertinent considerations for the 
obstetric team in charge of pregnancy care of the female CCS. Further research 
is needed however, to prove that any suggested interventions might influence 
perinatal outcomes of CCS.    
Communication of potential adverse outcomes for CCS in pregnancy and birth 
is also an important issue for care. Female CCS and their families should feel 
informed and empowered to be active partners in their pregnancy care, 
provided with a full clinical picture of evidence-based research to make their 
care choices. More research is needed to find the most appropriate time to 
provide female CCS with pregnancy and birth long-term effects information, 
including an exploration of how to increase the awareness of potential adverse 
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outcomes for health care professionals from paediatric oncology, long-term 
follow up and maternity care providers responsible for the care of the female 
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vii) Appendices  
Appendix 1 – PRISMA reporting guidelines  




TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: background; 
objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic 
review registration number.  
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is 
already known.  
 
Objectives  4 Provide an explicit statement of questions being addressed with 
reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed 
(e.g., Web address), and, if available, provide registration 




6 Specify study characteristics (e.g., PICOS, length of follow-up) and 
report characteristics (e.g., years considered, language, publication 




7 Describe all information sources (e.g., databases with dates of 
coverage, contact with study authors to identify additional studies) in 
the search and date last searched.  
 
Search  8 Present full electronic search strategy for at least one database, 
including any limits used, such that it could be repeated.  
 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, 





10 Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and 
confirming data from investigators.  
 
Data items  11 List and define all variables for which data were sought (e.g., 
PICOS, funding sources) and any assumptions and simplifications 
made.  
 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of individual 
studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in 











14 Describe the methods of handling data and combining results of 








Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the 
cumulative evidence (e.g., publication bias, selective reporting 




16 Describe methods of additional analyses (e.g., sensitivity or 
subgroup analyses, meta-regression), if done, indicating which were 
pre-specified.  
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and 
included in the review, with reasons for exclusions at each stage, 




18 For each study, present characteristics for which data were 
extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations.  
 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, any 





20 For all outcomes considered (benefits or harms), present, for each 
study: (a) simple summary data for each intervention group (b) 




21 Present results of each meta-analysis done, including confidence 
intervals and measures of consistency.  
 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies 




23 Give results of additional analyses, if done (e.g., sensitivity or 
subgroup analyses, meta-regression [see Item 16]).  
 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for 
each main outcome; consider their relevance to key groups (e.g., 
healthcare providers, users, and policy makers).  
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), 
and at review-level (e.g., incomplete retrieval of identified research, 
reporting bias).  
 
Conclusions  26 Provide a general interpretation of the results in the context of other 
evidence, and implications for future research.  
 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other 







Appendix 2 – PPIE survey 
Female childhood cancer survivors and birth outcomes 
Q1 Thank you for agreeing to take part in this questionnaire.   We want to have 
a better understanding of the effects of radiotherapy given to children with 
cancer from a patient/parent point of view. If you/your child received: - 
Radiotherapy as part of their cancer treatment and they are a girl, we would like 
to know what issues you/your child would consider to be important for a mother 
and baby during pregnancy and birth.  
We are also interested in any thoughts about issues that may concern you/your 
child when thinking of planning a family.  As part of a masters by research 
programme (funded by the HEE/NIHR and Coventry University), Angela 
Polanco (Research midwife and bereaved parent) will be undertaking a review 
of the evidence to see if there is any links with radiotherapy, given in childhood 
for cancer, on live birth and looking at any associated complications for 
women/babies during pregnancy and birth. Many thanks for your time. 
Q2 What is your background... 
 Parent of a child (1) 
 Survivor who hasn't had a child (2) 
 Survivor who has had a child (3) 
Q3 As part of your/your child's treatment, did you/they receive radiotherapy to 
the tummy? 
 Yes (1) 
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 No (2) 
 Unsure (3) 
Q4 Do you know how much radiation you/your child received? 
 Yes (1) 
 Maybe (2) 
 No (3) 
Q5 If you do know how much radiotherapy was given please write below (total 
Gy) 
Q6 If you/your child received radiotherapy to the tummy, at what age did 
you/they receive this? 
 0-4 years (1) 
 5-10 years (2) 
 11-16 years (3) 
Q7 Have you been told that your/your child's treatments for cancer are likely to 
affect fertility (ability to have a baby)? 
 Definitely yes (1) 
 Probably yes (2) 
 Probably not (3) 
 Definitely not (4) 
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Q8 After completing treatment for cancer (including radiotherapy), what would 
you/your child be most concerned about during a pregnancy? Please rank your 
answers from most important to least important. 
______ Miscarriage (1) 
______ Early Labour (2) 
______ Small Baby (3) 
______ A healthy baby (4) 
______ Pregnancy complications for mother (5) 
______ Abnormalities in the baby (6) 
______ Risk of the baby having cancer (7) 
Q9 Are there any other issues during pregnancy or birth that you think might be 
important? 
Q10 Are you aware of any information given to survivors of childhood cancer 
about pregnancy after treatment has finished? 
 Yes (1) 
 No (2) 
Q11 If you/your child have been given such information, at what point were you 
given this? 
 Diagnosis (1) 
 During treatment (2) 
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 Upon remission (3) 
 When thinking about starting a family (4) 
 When pregnant (5) 
Q12 Thank you for participating in this questionnaire. Your responses will be 
used anonymously to help shape a master’s research project into the possible 
impact of radiotherapy, given for childhood for cancer, on live birth and any 
associated complications or for women with this history.  
You have the right not to take part in this survey at any time, and/or withdraw 
your responses at any time within 2 weeks of taking part. You do not need to 
give a reason for this and this will not affect any care or support provided by 
your clinical team.  
Content removed due to data protection considerations.
 
142 
Appendix 3 – PICO used for review  
PICO – Search terms 
 
Question: With Adult survivors of childhood cancer does Radiotherapy to the abdomen or 
pelvis effect Term Live birth rate 
 
Patient/Problem         Intervention   Outcomes         Not    
Childhood cancer  
Childhood 
neoplasm 
 Radiotherapy  Live birth  miscarriage  Non-English 
Or Or Or Or Or 
Wilms tumour 
Renal tumour  
Abdomen Full term stillbirth IVF 










Or Or Or Or Or 
Hepatoblastoma 
Liver cancer 
Hepatic tumours  





Or Or Or Or Or 
Patient 
Problem  
Adult survivors of childhood cancer  
Intervention Radiotherapy to the flank, abdomen or pelvis 
Comparator General population, siblings  





  Premature 
birth 
Male 




  Growth 
restriction 
Small baby 
Breast cancer  
Or  Or  Or Or  Or  
Teenage cancer 
Young adult  
Adolescent cancer  
     Caesarean 
section  
  
Or       Or    
rhabdomyosarcoma      Labour type   




     Labour 
complications  
  
Or      Or    
Childhood 
malignancy  
















Appendix 5 – PROSPERO registration  
Removed due to data protection considerations
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Appendix 6 – MEDLINE sample search strategy  
Question: With Adult survivors of childhood cancer does Radiotherapy to the abdomen or 
pelvis effect Term Live birth rate 
 
Childhood cancer  
Childhood 
neoplasm 
 Radiotherapy  Live birth  miscarriage  English 
Or Or Or Or Or 
Wilms tumour 
Renal tumour  
Abdomen Full term stillbirth IVF 










Or Or Or Or Or 
Hepatoblastoma 
Liver cancer 
Hepatic tumours  





Or Or Or Or Or 
Germ cell 
 
  Premature 
birth 
male 








Or  Or  Or Or  Or  
Teenage cancer 
Young adult  





Adolescent cancer  
Or       Or    
rhabdomyosarcoma      Labour type   
      Or    
Or       Labour 
complications  
  
      Or    








Terms Search Options Actions 
 
S1 TI childhood 
cancer AND TI 
surviv*  





S2 AB childhood 
cancer AND AB 
surviv*  










S4 TX british 
childhood cancer 
survivorship 
study OR TX 
BCCSS  



















S7 TI PREGNAN* 
OR AB 
PREGNAN*  










S9 (MH "Birth Rate") 
OR (MH "Term 
Birth") OR (MH 
"Live Birth") OR 
(MH 
"Parturition")  















Infant, Newborn: birth-1 month; 
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All Infant: birth-23 months; 
Infant: 1-23 months; 
Child, Preschool: 2-5 years; 
Child: 6-12 years; 
Adolescent: 13-18 years;  
All Child: 0-18 years;  




Appendix 7 – Modified data extraction template  
Data collection form 
Angela Polanco –Mres adapted form to be inputted onto EPPI-reviewer for completion by 1st 
and second reviewer.  
Review title or ID 
      
 
Study ID (surname of first author and year first full report of study was published e.g. Smith 2001)  
      
 
Report IDs of other reports of this study (e.g. duplicate publications, follow-up studies) 
      
 
Notes:         
 
General Information 
1. Date form completed 
(dd/mm/yyyy) 
      
2. Name/ID of person extracting 
data 
      
3. Report title  
(title of paper/ abstract/ report 
that data are extracted from) 
      
4. Report ID 
(if there are multiple reports of 
this study) 
      
5. Reference details       
6. Report author contact details       
7. Publication type 
(e.g. full report, abstract, letter) 
      
8. Study funding source 
(including role of funders) 
      
 
152 
Possible conflicts of interest 
(for study authors) 
      





Review Inclusion Criteria 
(Insert inclusion criteria for each 
characteristic as defined in the 
Protocol) 
Yes/ No / 
Unclear 
Location in text 
(pg & ¶/fig/table) 
10. Type of study Cohort study ...       
Case-control  ...       
Randomised controlled study ...       
Other design (specify): 
      
... 
      
11. Age of 
Participants 
      ...       
12. Types of 
intervention 
      ...       
13. Types of 
outcome 
measures 
      ...       
14. Decision: ... 
15. Reason for 
exclusion 
      
16. Notes:        
 
DO NOT PROCEED IF STUDY EXCLUDED FROM REVIEW 
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Population and setting 
 Description 
Include comparative 
information for each group 
(i.e. intervention and 
controls) if available 
Location in text 
(pg & ¶/fig/table) 
17. Population 
description 
(from which study 
participants are 
drawn) 
            
18. Setting 
(including location 
and social context) 
            
19. Inclusion criteria              
20. Exclusion criteria             
21. Method/s of 
recruitment of 
participants 
            




23. Notes:   
 
Methods 
 Descriptions as stated in 
report/paper 
Location in text 
(pg & ¶/fig/table) 




            
26. Data source (registry 
data, questionnaire) 
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27. Start date       
 
      
28. End date       
 
      
29. Duration of 
participation 
(from recruitment to 
last follow-up) 
            
30. Notes:        
 
Risk of Bias assessment 
Please use attached Newcastle Ottawa Scale form for either cohort or Case-Control study  
Scale score  (stars) 
High or low risk  High/low  
 
Participants 
Provide overall data and, if available, comparative data for each intervention or comparison group. 
 Description as stated in 
report/paper 
Location in text 
(pg & ¶/fig/table) 
31. Total no. included   
(or total pop. at start of 
study for NRCTs) 
            
32. Control population 
number  
            
33. Baseline data comments              
34. Withdrawals and 
exclusions 
(if not provided below by 
outcome) 
            
35. Age             
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 Description as stated in 
report/paper 
Location in text 
(pg & ¶/fig/table) 
36. Sex             
37. Race/Ethnicity             
38. Country of domicile    
39. Type of cancer              
40. Age at diagnosis              
41. Age at birth    
42. Treatment received 
(chemo/radio/combinati
on) 
            
43. Dose of radiotherapy 
given 
  
44. Other relevant 
sociodemographic 
            
45. Subgroups measured             
46. Subgroups reported             
47. Notes:        
 
Control groups  
Copy and paste table for each intervention and comparison group  
Control group (if identified) 
 Description as stated in 
report/paper 
Location in text 
(pg & ¶/fig/table) 
48. Group size              
49. Method of recruitment              
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 Description as stated in 
report/paper 
Location in text 
(pg & ¶/fig/table) 
50. Description  
(include sufficient detail for 
replication, e.g. content, 




            
51. Duration of observation 
period 
            
52. Timing  
(e.g. frequency, duration of 
each episode) 
            
53. Delivery  
(e.g. mechanism, medium, 
intensity, fidelity) 
            
54. Providers 
(e.g. no., profession, 
training, ethnicity etc. if 
relevant) 
            
55. Co-interventions             
56. Economic variables 
(i.e. intervention cost, 
changes in other costs as 
result of intervention) 
            
57. Resource requirements to 
replicate intervention  
(e.g. staff numbers, cold 
chain, equipment) 
            
58. Notes:        
 
Outcomes 




 Description as stated in 
report/paper 
Location in text 
(pg & ¶/fig/table) 
59. Outcome name             
60. Time points measured 
(specify whether from 
start or end of 
intervention) 
            
61. Time points reported             
62. Outcome definition  
(with diagnostic criteria if 
relevant and note 
whether the outcome is 
desirable or undesirable 
if this is not obvious) 
            
63. Person measuring/ 
reporting 
            
64. Unit of measurement  
(if relevant) 
            
65. Scales: upper and lower 
limits  
(indicate whether high or 
low score is good) 
            







      
67. Consent process              
68. Notes:        
 
Results 
EPPI-Reviewer software will record all results.  
Applicability 
69. Have important 
populations been 
excluded from the study?  
... 
Yes/No/Unclear 




populations, and possible 
differences in the 
intervention effect)  
70. Does the study directly 
address the review 
question? 




      
71. Notes:        
 
Other information 
 Description as stated in 
report/paper 
Location in text 
(pg & ¶/fig/table) 
72. Key conclusions of study 
authors 
            
73. References to other 
relevant studies 
            
74. Correspondence required 
for further study 
information  
(what and from whom) 
      
75. Further study 
information requested 
(from whom, what and 
when) 
 
76. Correspondence received  







Appendix 8 - Newcastle Ottawa Scale  
NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE 
 COHORT STUDIES 
Some materials have been removed from this thesis due to Third Party Copyright and confidentiality 
considerations. Pages where material has been removed are clearly marked in the electronic version. The 
unabridged version of the thesis can be viewed at the Lanchester Library, Coventry University.
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Economics of Review Expenditure Funding Source 
Cost 
Researcher Costs 
Researcher unknown NIHR/HEE funding for part time 2 year course NHS band 6 
Independent Reviewer unknown NIHR/HEE Fellowship
Director of Studies unknown Coventry University Salary
Software 
Covidence 250 (approx £200 Coventry University Post Graduate (PGR) Bursary
Printing and consumables 
Miscellaneous £50 (Parking) Researcher to fund 
Article sourcing £2 per article or Nil Coventry University PGR Bursary 
Photocopying Nil Coventry University/UHCW NHS trust
Printing Nil Coventry University printer credit allowance 
Training 
Systematic Review Course £100 Coventry University PGR Bursary 




Appendix 10 – Gantt chart  
 
Version 2.0 (updated) 
 
 
2016-17 Month Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug
University Induction 
Module 1 study 
Module 2 study
Research question, methodology and aims - review and develop 
Database and Literature search - pregnancy outcomes 
critical analysis of key publications and data 
identification of key outcomes 
writing up of results from primary search 
Key 2016-17




2017-18 Month Sep Oct Nov Dec Jan Feb Mar Apr May June
Database and literature review - exisitng and similar pregnancy care pathways  
Critical analysis of data 
assessing application of results to prospective client group
final thesis writing 
submission 
dissemination of results/publication writing 
application for further funding/study
Key 2017-18
Month 1 commencing 27/09/2017
Christmas Break 
Easter Break 
Mres project timeline 
Mres project timeline 
2017 Month Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sept Nov Dec
University Induction 
Module 1 study 
Module 2 study
Research question, methodology and aims
Finalise Protocol
Ethical Approval, register on Prospero
Database and Literature search
Data Extraction and synthesis 
Meta-Analysis
critical analysis and discussion
Clinical Portfolio completion 
2018 Month Jan Feb Mar Apr May Jun Jul Aug Sep
critical analysis and discussion
final thesis writing 
submission 
dissemination of results/publication writing 






Mres project timeline 
Mres project timeline 
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Appendix 11 – Full Meta-analysis reports 
 Meta-analysis  
Live birth CCS vs non-exposed CCS  
Main Summary 
 
Random-Effects Model (k = 5; tau^2 estimator: DL) 
 
tau^2 (estimated amount of total heterogeneity): 0.6689 (SE = 
0.5505) 
tau (square root of estimated tau^2 value):      0.8179 
I^2 (total heterogeneity / total variability):   98.54% 
H^2 (total variability / sampling variability):  68.73 
 
Test for Heterogeneity: 




estimate       se     zval     pval    ci.lb    ci.ub 
-0.1069   0.3694  -0.2893   0.7723  -0.8310   0.6172 
 
--- 





logLik:   -5.500612 
deviance: 24.335929 
AIC:      15.001223 
BIC:      14.220099 




estimate   ci.lb    ci.ub 
tau^2    0.6689  0.2160   5.2143 
tau      0.8179  0.4647   2.2835 
I^2(%)  98.5450 95.6269  99.8110 












Funnel plot (Sampling Variance) 
 




Funnel plot (Inverse Sampling Variance) 
 





Normal QQ Plot (for selected statistical model) 
 






















Pre term birth CCS vs non-exposed CCS  
Main Summary 
 
Random-Effects Model (k = 5; tau^2 estimator: DL) 
 
tau^2 (estimated amount of total heterogeneity): 0 (SE = 0.0369) 
tau (square root of estimated tau^2 value):      0 
I^2 (total heterogeneity / total variability):   0.00% 
H^2 (total variability / sampling variability):  1.00 
 
Test for Heterogeneity: 




estimate       se     zval     pval    ci.lb    ci.ub 
1.1862   0.0967  12.2629   <.0001   0.9966   1.3758      *** 
 
--- 





logLik:   1.090524 
deviance: 1.849992 
AIC:      1.818952 
BIC:      1.037828 




estimate  ci.lb   ci.ub 
tau^2    0.0000 0.0000  0.9051 
tau      0.0000 0.0000  0.9514 
I^2(%)   0.0000 0.0000 94.5556 












Funnel plot (Sampling Variance) 
 
 





Funnel plot (Inverse Sampling Variance) 
 
 





Normal QQ Plot (for selected statistical model) 
 
 









Live birth CCS vs Sibling  
Main Summary 
 
Random-Effects Model (k = 3; tau^2 estimator: DL) 
 
tau^2 (estimated amount of total heterogeneity): 0.0351 (SE = 
0.0460) 
tau (square root of estimated tau^2 value):      0.1874 
I^2 (total heterogeneity / total variability):   84.12% 
H^2 (total variability / sampling variability):  6.30 
 
Test for Heterogeneity: 




estimate       se     zval     pval    ci.lb    ci.ub 
-0.2963   0.1205  -2.4588   0.0139  -0.5324  -0.0601        * 
 
--- 





logLik:    0.368944 
deviance:  8.569461 
AIC:       3.262112 
BIC:       1.459337 








Funnel plot (Sampling Variance) 
 




Funnel plot (Inverse Sampling Variance) 
 



























Stillbirth CCS vs non-exposed CCS  
Main Summary 
 
Random-Effects Model (k = 4; tau^2 estimator: DL) 
 
tau^2 (estimated amount of total heterogeneity): 0 (SE = 0.1662) 
tau (square root of estimated tau^2 value):      0 
I^2 (total heterogeneity / total variability):   0.00% 
H^2 (total variability / sampling variability):  1.00 
 
Test for Heterogeneity: 




estimate       se     zval     pval    ci.lb    ci.ub 
0.4846   0.1988   2.4373   0.0148   0.0949   0.8742        * 
 
--- 





logLik:   -1.979876 
deviance:  1.895957 
AIC:       7.959753 
BIC:       6.732341 




estimate  ci.lb   ci.ub 
tau^2    0.0000 0.0000  4.7612 
tau      0.0000 0.0000  2.1820 
I^2(%)   0.0000 0.0000 95.9005 







Funnel plot (Standard Error) 
 
 




Funnel plot (Inverse Standard Error) 
 
 





Radial (Galbraith) Plot 
 
Normal QQ Plot (for selected statistical model) 
 








Miscarriage CCS vs non-exposed CCS 
Main Summary 
 
Random-Effects Model (k = 3; tau^2 estimator: DL) 
 
tau^2 (estimated amount of total heterogeneity): 0.0060 (SE = 
0.0285) 
tau (square root of estimated tau^2 value):      0.0771 
I^2 (total heterogeneity / total variability):   21.10% 
H^2 (total variability / sampling variability):  1.27 
 
Test for Heterogeneity: 




estimate       se     zval     pval    ci.lb    ci.ub 
0.3251   0.0901   3.6074   0.0003   0.1485   0.5018      *** 
 
--- 







logLik:    1.1864867 
deviance:  3.1372145 
AIC:       1.6270266 
BIC:      -0.1757488 











Appendix 12 – Risk of bias scores  
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix 13 – Algorithm for risk for stillbirth 
 
